HRP20210450T1 - Biciklički heterociklusni spojevi i njihova uporaba u terapiji - Google Patents
Biciklički heterociklusni spojevi i njihova uporaba u terapiji Download PDFInfo
- Publication number
- HRP20210450T1 HRP20210450T1 HRP20210450TT HRP20210450T HRP20210450T1 HR P20210450 T1 HRP20210450 T1 HR P20210450T1 HR P20210450T T HRP20210450T T HR P20210450TT HR P20210450 T HRP20210450 T HR P20210450T HR P20210450 T1 HRP20210450 T1 HR P20210450T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- dimethyl
- pyrrolo
- pyridin
- methylpiperazin
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 32
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 26
- 125000000623 heterocyclic group Chemical group 0.000 claims 26
- 125000004452 carbocyclyl group Chemical group 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 150000002431 hydrogen Chemical group 0.000 claims 8
- -1 5-Bromo-1-[2-((R)-3-methyl-piperazin-1-yl)-acetyl]-2,3-dihydro-1H-indole-6-sulfinic acid methylamide hydrochloride salt Chemical compound 0.000 claims 7
- 238000011321 prophylaxis Methods 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 4
- 238000010511 deprotection reaction Methods 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- XIQKDUKFFKQZAO-DNRQZRRGSA-N 1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[[(3r)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone Chemical compound C([C@H](NC[C@@H]1CN2[C@@H](COCC2)C)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1 XIQKDUKFFKQZAO-DNRQZRRGSA-N 0.000 claims 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 108091007065 BIRCs Proteins 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims 2
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 2
- 230000002071 myeloproliferative effect Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- ONHMJBSOSWPDAC-VMJMSTHCSA-N (2r,5r)-1-[2-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl)-2-oxoethyl]-n,n,5-trimethylpiperazine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CN(C)C(=O)[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CN=C2C(C)(C)C1 ONHMJBSOSWPDAC-VMJMSTHCSA-N 0.000 claims 1
- PFBFTZDMVYIOGT-WZONZLPQSA-N (2r,5r)-1-[2-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-oxoethyl]-n,n,5-trimethylpiperazine-2-carboxamide Chemical compound CN(C)C(=O)[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=NC=C2C(C)(C)C1 PFBFTZDMVYIOGT-WZONZLPQSA-N 0.000 claims 1
- BVIFFTSMIJDYLH-VQZRABBESA-N (2r,5r)-1-[2-(6-chloro-3,3-dimethyl-2h-indol-1-yl)-2-oxoethyl]-n,5-dimethylpiperazine-2-carboxamide;hydrochloride Chemical compound Cl.CNC(=O)[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C(C)(C)C1 BVIFFTSMIJDYLH-VQZRABBESA-N 0.000 claims 1
- BELQROCTNGHBAR-OKOCIGOVSA-N (2r,5r)-1-[2-[6-(2-chlorophenoxy)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-n,n,5-trimethylpiperazine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CN(C)C(=O)[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(OC=3C(=CC=CC=3)Cl)=NC=C2C(C)(C)C1 BELQROCTNGHBAR-OKOCIGOVSA-N 0.000 claims 1
- WNTSSVFVLJAVFP-KTWHHOSASA-N (2r,5r)-1-[2-[6-(benzenesulfonyl)-5-fluoro-3,3-dimethyl-2h-indol-1-yl]-2-oxoethyl]-n,5-dimethylpiperazine-2-carboxamide;hydrochloride Chemical compound Cl.CNC(=O)[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C=3C=CC=CC=3)=C(F)C=C2C(C)(C)C1 WNTSSVFVLJAVFP-KTWHHOSASA-N 0.000 claims 1
- RQFXPBHBXDLBTR-GARQXEGOSA-N (2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-n,n,5-trimethylpiperazine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CN(C)C(=O)[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C(=CC(F)=CC=3)F)=NC=C2C(C)(C)C1 RQFXPBHBXDLBTR-GARQXEGOSA-N 0.000 claims 1
- UXEPHRISZORIDG-UOHPHXQYSA-N (2r,5r)-1-[2-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-n,n,5-trimethylpiperazine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CN(C)C(=O)[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C(F)(F)C=3C=CC=CC=3)=NC=C2C(C)(C)C1 UXEPHRISZORIDG-UOHPHXQYSA-N 0.000 claims 1
- BJMFWDSENUKNTE-WIPBKKOOSA-N (2r,5r)-1-[2-[6-benzyl-3-methyl-3-(phenylmethoxymethyl)-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-n,n,5-trimethylpiperazine-2-carboxamide Chemical compound CN(C)C(=O)[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=NC=C2C(C)(COCC=2C=CC=CC=2)C1 BJMFWDSENUKNTE-WIPBKKOOSA-N 0.000 claims 1
- DYXVCQMOKHZKMO-IOZGHAEBSA-N (3r)-1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3-methyl-3-phenyl-2h-indole-6-carbonitrile Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C#N)=CC=C2[C@@](C)(C=2C=CC=CC=2)C1 DYXVCQMOKHZKMO-IOZGHAEBSA-N 0.000 claims 1
- HCWUWDXVZPKWTB-NMJGOYCLSA-N (3r)-3-methyl-1-[2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]acetyl]-3-phenyl-2h-indole-6-carbonitrile Chemical compound C1([C@@]2(C)CN(C3=CC(=CC=C32)C#N)C(=O)CN2C[C@H](NC[C@@H]2C(=O)N2CCOCC2)C)=CC=CC=C1 HCWUWDXVZPKWTB-NMJGOYCLSA-N 0.000 claims 1
- QVLZUJSECVNNFP-SZEHJLNQSA-N (3r)-3-methyl-1-[2-[(2r,5r)-5-methyl-2-(pyrazol-1-ylmethyl)piperazin-1-yl]acetyl]-3-phenyl-2h-indole-6-carbonitrile Chemical compound C1([C@@]2(C)CN(C3=CC(=CC=C32)C#N)C(=O)CN2C[C@H](NC[C@@H]2CN2N=CC=C2)C)=CC=CC=C1 QVLZUJSECVNNFP-SZEHJLNQSA-N 0.000 claims 1
- DYXVCQMOKHZKMO-JYMRHQFYSA-N (3s)-1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3-methyl-3-phenyl-2h-indole-6-carbonitrile Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C#N)=CC=C2[C@](C)(C=2C=CC=CC=2)C1 DYXVCQMOKHZKMO-JYMRHQFYSA-N 0.000 claims 1
- HCWUWDXVZPKWTB-VGTADKHUSA-N (3s)-3-methyl-1-[2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]acetyl]-3-phenyl-2h-indole-6-carbonitrile Chemical compound C1([C@]2(C)CN(C3=CC(=CC=C32)C#N)C(=O)CN2C[C@H](NC[C@@H]2C(=O)N2CCOCC2)C)=CC=CC=C1 HCWUWDXVZPKWTB-VGTADKHUSA-N 0.000 claims 1
- QVLZUJSECVNNFP-LXHIVTORSA-N (3s)-3-methyl-1-[2-[(2r,5r)-5-methyl-2-(pyrazol-1-ylmethyl)piperazin-1-yl]acetyl]-3-phenyl-2h-indole-6-carbonitrile Chemical compound C1([C@]2(C)CN(C3=CC(=CC=C32)C#N)C(=O)CN2C[C@H](NC[C@@H]2CN2N=CC=C2)C)=CC=CC=C1 QVLZUJSECVNNFP-LXHIVTORSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims 1
- PCNFTUCVOVDHHQ-FQRUVTKNSA-N 1'-[2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]acetyl]spiro[1,3-dihydroindene-2,3'-2h-indole]-6'-carbonitrile Chemical compound O=C([C@@H]1N(CC(=O)N2C3=CC(=CC=C3C3(CC4=CC=CC=C4C3)C2)C#N)C[C@H](NC1)C)N1CCOCC1 PCNFTUCVOVDHHQ-FQRUVTKNSA-N 0.000 claims 1
- IKYKVDPBZRTUSH-PXDATVDWSA-N 1'-[2-[(2r,5r)-5-methyl-2-[(4-methylpyrazol-1-yl)methyl]piperazin-1-yl]acetyl]spiro[1,3-dihydroindene-2,3'-2h-indole]-6'-carbonitrile Chemical compound C([C@@H]1N(CC(=O)N2C3=CC(=CC=C3C3(CC4=CC=CC=C4C3)C2)C#N)C[C@H](NC1)C)N1C=C(C)C=N1 IKYKVDPBZRTUSH-PXDATVDWSA-N 0.000 claims 1
- NKONMNAHMBGLGP-XFULWGLBSA-N 1-(1'-acetyl-6-chlorospiro[2h-indole-3,4'-piperidine]-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C2(CCN(CC2)C(C)=O)C1 NKONMNAHMBGLGP-XFULWGLBSA-N 0.000 claims 1
- ZKEAJFPUDNSYIF-GFCCVEGCSA-N 1-(2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC=CC=C2CC1 ZKEAJFPUDNSYIF-GFCCVEGCSA-N 0.000 claims 1
- YTMXGEJOAZDOBM-NVJADKKVSA-N 1-(2,3-dihydropyrrolo[2,3-b]pyridin-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C1CN[C@H](C)CN1CC(=O)N1C2=NC=CC=C2CC1 YTMXGEJOAZDOBM-NVJADKKVSA-N 0.000 claims 1
- SCKBWJIDYXIBKF-LLVKDONJSA-N 1-(2,3-dihydropyrrolo[3,2-c]pyridin-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC=NC=C2CC1 SCKBWJIDYXIBKF-LLVKDONJSA-N 0.000 claims 1
- XUEVYSZTXUOGCJ-CYBMUJFWSA-N 1-(3,3-dimethyl-2h-indol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC=CC=C2C(C)(C)C1 XUEVYSZTXUOGCJ-CYBMUJFWSA-N 0.000 claims 1
- RFONHGSWQKOABD-JAXOOIEVSA-N 1-(3,3-dimethyl-6-phenoxy-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(OC=3C=CC=CC=3)=NC=C2C(C)(C)C1 RFONHGSWQKOABD-JAXOOIEVSA-N 0.000 claims 1
- BODYKIYKAUPLOM-FXKISCCRSA-N 1-(3,3-dimethyl-6-thiophen-3-yl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C3=CSC=C3)=NC=C2C(C)(C)C1 BODYKIYKAUPLOM-FXKISCCRSA-N 0.000 claims 1
- ZFPFQGHPNXJYDC-LCHCQGBESA-N 1-(3-benzyl-6-chloro-3-methyl-2h-indol-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C(C)(CC=2C=CC=CC=2)C1 ZFPFQGHPNXJYDC-LCHCQGBESA-N 0.000 claims 1
- AUZHITAHPJVHEB-MNMPKAIFSA-N 1-(3-chloro-7,7-dimethyl-6h-pyrrolo[3,2-c]pyridazin-5-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=NN=C2C(C)(C)C1 AUZHITAHPJVHEB-MNMPKAIFSA-N 0.000 claims 1
- NSKFPEBFGUWQBA-RFVHGSKJSA-N 1-(4,6-dichloro-3,3-dimethyl-2h-indol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C(C=C(Cl)C=C2Cl)=C2C(C)(C)C1 NSKFPEBFGUWQBA-RFVHGSKJSA-N 0.000 claims 1
- JSTNBKVECVAHEM-GFCCVEGCSA-N 1-(4-chloro-3,3-dimethyl-2h-indol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C(C=CC=C2Cl)=C2C(C)(C)C1 JSTNBKVECVAHEM-GFCCVEGCSA-N 0.000 claims 1
- WLDUPKFJTCAKBF-LLVKDONJSA-N 1-(5-bromo-2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC=C(Br)C=C2CC1 WLDUPKFJTCAKBF-LLVKDONJSA-N 0.000 claims 1
- XOMZQKAQYWEISN-LLVKDONJSA-N 1-(5-fluoro-2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC=C(F)C=C2CC1 XOMZQKAQYWEISN-LLVKDONJSA-N 0.000 claims 1
- HKNIBOSLZFXXBR-FMOMHUKBSA-N 1-(5-fluoro-3,3-dimethyl-6-propan-2-ylsulfonyl-2h-indol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C1C(C)(C)C=2C=C(F)C(S(=O)(=O)C(C)C)=CC=2N1C(=O)CN1CCN[C@H](C)C1 HKNIBOSLZFXXBR-FMOMHUKBSA-N 0.000 claims 1
- ASPJNEJMKDSZQH-QCUBGVIVSA-N 1-(5-fluoro-3,3-dimethyl-6-pyrrolidin-1-ylsulfonyl-2h-indol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)N3CCCC3)=C(F)C=C2C(C)(C)C1 ASPJNEJMKDSZQH-QCUBGVIVSA-N 0.000 claims 1
- FSARZEHAEWYDMG-XFULWGLBSA-N 1-(5-fluoro-6-phenyl-2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(C=3C=CC=CC=3)=C(F)C=C2CC1 FSARZEHAEWYDMG-XFULWGLBSA-N 0.000 claims 1
- UZLRFCCQAQKCNP-DTPOWOMPSA-N 1-(5-methoxy-3,3-dimethyl-2h-pyrrolo[2,3-c]pyridin-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CN=C(OC)C=C2C(C)(C)C1 UZLRFCCQAQKCNP-DTPOWOMPSA-N 0.000 claims 1
- LSUUOTSIQAKOJE-DYESRHJHSA-N 1-(6'-chlorospiro[1,3-dihydroindene-2,3'-2h-indole]-1'-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C2(CC3=CC=CC=C3C2)C1 LSUUOTSIQAKOJE-DYESRHJHSA-N 0.000 claims 1
- BZSUEZLILNWUHL-AQHBPOCSSA-N 1-(6'-chlorospiro[1,3-dihydroindene-2,3'-2h-indole]-1'-yl)-2-[(2r,5r)-5-methyl-2-(pyrazol-1-ylmethyl)piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@@H]1N(CC(=O)N2C3=CC(Cl)=CC=C3C3(CC4=CC=CC=C4C3)C2)C[C@H](NC1)C)N1C=CC=N1 BZSUEZLILNWUHL-AQHBPOCSSA-N 0.000 claims 1
- TVNXFZNGOQHVTR-LLVKDONJSA-N 1-(6-amino-2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(N)=CC=C2CC1 TVNXFZNGOQHVTR-LLVKDONJSA-N 0.000 claims 1
- CKQIYZJDLLSXSX-PKLMIRHRSA-N 1-(6-anilino-2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1CN[C@H](C)CN1CC(=O)N1C2=CC(NC=3C=CC=CC=3)=CC=C2CC1 CKQIYZJDLLSXSX-PKLMIRHRSA-N 0.000 claims 1
- GCXVKCURSDVWSG-POCMBTLOSA-N 1-(6-anilino-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(NC=3C=CC=CC=3)=NC=C2C(C)(C)C1 GCXVKCURSDVWSG-POCMBTLOSA-N 0.000 claims 1
- JCJFDRHRSYEJCB-IEBWSBKVSA-N 1-(6-benzoyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C(=O)C=3C=CC=CC=3)=NC=C2C(C)(C)C1 JCJFDRHRSYEJCB-IEBWSBKVSA-N 0.000 claims 1
- BNGKUAZMXYXWOG-PKLMIRHRSA-N 1-(6-benzyl-2,3-dihydropyrrolo[3,2-c]pyridin-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=NC=C2CC1 BNGKUAZMXYXWOG-PKLMIRHRSA-N 0.000 claims 1
- ARNTYDWEKNIENM-IUFJOMBNSA-N 1-(6-benzyl-3,3-dimethyl-2h-indol-1-yl)-2-[(2r,5r)-2-(hydroxymethyl)-5-methylpiperazin-1-yl]ethanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CC=C2C(C)(C)C1 ARNTYDWEKNIENM-IUFJOMBNSA-N 0.000 claims 1
- GPDPIVHMJSJBPD-DENIHFKCSA-N 1-(6-benzyl-3,3-dimethyl-2h-indol-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CC=C2C(C)(C)C1 GPDPIVHMJSJBPD-DENIHFKCSA-N 0.000 claims 1
- WGWQFUTUISTDAA-QFQXNSOFSA-N 1-(6-benzyl-3,3-dimethyl-2h-indol-1-yl)-2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]ethanone Chemical compound C([C@H](NC[C@@H]1C(=O)N2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CC=C2CC1=CC=CC=C1 WGWQFUTUISTDAA-QFQXNSOFSA-N 0.000 claims 1
- NXUPJTVIQXMZID-IUFJOMBNSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[2,3-b]pyridin-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=NC(CC=3C=CC=CC=3)=CC=C2C(C)(C)C1 NXUPJTVIQXMZID-IUFJOMBNSA-N 0.000 claims 1
- MTEYJTPOEPRTKN-IUFJOMBNSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CN=C2C(C)(C)C1 MTEYJTPOEPRTKN-IUFJOMBNSA-N 0.000 claims 1
- HZAIITNPYFOXSV-CHOFETAFSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2r,5r)-2-[(4-fluoropyrazol-1-yl)methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2N=CC(F)=C2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=CC=C1 HZAIITNPYFOXSV-CHOFETAFSA-N 0.000 claims 1
- YUTWGPURXMCENH-OYNPXDHBSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1C(=O)N2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=CC=C1 YUTWGPURXMCENH-OYNPXDHBSA-N 0.000 claims 1
- AUAVBXHNZZSHRV-KTWHHOSASA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-2-(difluoromethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.FC(F)[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=NC=C2C(C)(C)C1 AUAVBXHNZZSHRV-KTWHHOSASA-N 0.000 claims 1
- NDFZYTRPCFAIDC-XLCHORMMSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-2-(fluoromethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.FC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=NC=C2C(C)(C)C1 NDFZYTRPCFAIDC-XLCHORMMSA-N 0.000 claims 1
- FSAFPMHTFIAMFU-IUFJOMBNSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=NC=C2C(C)(C)C1 FSAFPMHTFIAMFU-IUFJOMBNSA-N 0.000 claims 1
- HBDGWQFGJDJDTE-AQHBPOCSSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-2-[(4-fluoropyrazol-1-yl)methyl]-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2N=CC(F)=C2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1 HBDGWQFGJDJDTE-AQHBPOCSSA-N 0.000 claims 1
- RAVJCUPSMXINES-CJFMBICVSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]ethanone Chemical compound C([C@H](NC[C@@H]1C(=O)N2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1 RAVJCUPSMXINES-CJFMBICVSA-N 0.000 claims 1
- XFKCLEAOAAAMSC-ZBZHFSFXSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-5-methyl-2-(piperidine-1-carbonyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1C(=O)N2CCCCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1 XFKCLEAOAAAMSC-ZBZHFSFXSA-N 0.000 claims 1
- PGEJFEPHINPWNA-NFBKMPQASA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-5-methyl-2-(pyrazol-1-ylmethyl)piperazin-1-yl]ethanone Chemical compound C([C@H](NC[C@@H]1CN2N=CC=C2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1 PGEJFEPHINPWNA-NFBKMPQASA-N 0.000 claims 1
- VYSPTIPYTGPKJA-SMVXIFJNSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-5-methyl-2-(pyrrolidine-1-carbonyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1C(=O)N2CCCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1 VYSPTIPYTGPKJA-SMVXIFJNSA-N 0.000 claims 1
- MWQIHKWZUBLJLH-MBUMRYSBSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-5-methyl-2-[(4-methylpyrazol-1-yl)methyl]piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2N=CC(C)=C2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1 MWQIHKWZUBLJLH-MBUMRYSBSA-N 0.000 claims 1
- VYGBPSIWAWZGTG-NQIIRXRSSA-N 1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2s,5r)-2-ethyl-5-methylpiperazin-1-yl]ethanone Chemical compound CC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=NC=C2C(C)(C)C1 VYGBPSIWAWZGTG-NQIIRXRSSA-N 0.000 claims 1
- KDEIBOSAHHMCJL-FYTYVHDFSA-N 1-(6-benzyl-3-methyl-3-pyridin-2-yl-2h-indol-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CC=C2C(C)(C=2N=CC=CC=2)C1 KDEIBOSAHHMCJL-FYTYVHDFSA-N 0.000 claims 1
- RWMKCHSNFHXRLV-UNZXCFIYSA-N 1-(6-benzyl-3-methyl-3-pyridin-3-yl-2h-indol-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CC=C2C(C)(C=2C=NC=CC=2)C1 RWMKCHSNFHXRLV-UNZXCFIYSA-N 0.000 claims 1
- NZDCLVMPVMGKMR-YYMFTFNESA-N 1-(6-benzylsulfonyl-3,3-dimethyl-2h-indol-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)CC=3C=CC=CC=3)=CC=C2C(C)(C)C1 NZDCLVMPVMGKMR-YYMFTFNESA-N 0.000 claims 1
- IWSITJSGTRUVTC-CXAGYDPISA-N 1-(6-bromo-2,3-dihydroindol-1-yl)-2-[(2s,5r)-5-methyl-2-propan-2-ylpiperazin-1-yl]ethanone Chemical compound CC(C)[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Br)=CC=C2CC1 IWSITJSGTRUVTC-CXAGYDPISA-N 0.000 claims 1
- NRALMRJMHWZEOC-LLVKDONJSA-N 1-(6-bromo-2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(Br)=CC=C2CC1 NRALMRJMHWZEOC-LLVKDONJSA-N 0.000 claims 1
- BSUPDLHHECKZJL-LLVKDONJSA-N 1-(6-chloro-2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2CC1 BSUPDLHHECKZJL-LLVKDONJSA-N 0.000 claims 1
- MPLKAEJQXQPGTN-HNCPQSOCSA-N 1-(6-chloro-2,3-dihydropyrrolo[3,2-c]pyridin-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=NC=C2CC1 MPLKAEJQXQPGTN-HNCPQSOCSA-N 0.000 claims 1
- VJOOKCSOTZSUQX-AYCGRUCCSA-N 1-(6-chloro-3,3-diethyl-2h-indol-1-yl)-2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.O=C([C@H]1CN[C@H](C)CN1CC(=O)N1CC(C2=CC=C(Cl)C=C21)(CC)CC)N1CCOCC1 VJOOKCSOTZSUQX-AYCGRUCCSA-N 0.000 claims 1
- NFFZQHULSPYLJT-QMDUSEKHSA-N 1-(6-chloro-3,3-dimethyl-2h-indol-1-yl)-2-[(2r,5r)-2-(hydroxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.OC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C(C)(C)C1 NFFZQHULSPYLJT-QMDUSEKHSA-N 0.000 claims 1
- GNHFCFMDHYWQPR-SWYZXDRTSA-N 1-(6-chloro-3,3-dimethyl-2h-indol-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C(C)(C)C1 GNHFCFMDHYWQPR-SWYZXDRTSA-N 0.000 claims 1
- YQWSAZNLFASMBH-DNVCBOLYSA-N 1-(6-chloro-3,3-dimethyl-2h-indol-1-yl)-2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]ethanone Chemical compound O=C([C@@H]1N(CC(=O)N2C3=CC(Cl)=CC=C3C(C)(C)C2)C[C@H](NC1)C)N1CCOCC1 YQWSAZNLFASMBH-DNVCBOLYSA-N 0.000 claims 1
- NNOMIHHWHPPSAI-SSPJITILSA-N 1-(6-chloro-3,3-dimethyl-2h-indol-1-yl)-2-[(2r,5r)-5-methyl-2-(pyrazol-1-ylmethyl)piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@@H]1N(CC(=O)N2C3=CC(Cl)=CC=C3C(C)(C)C2)C[C@H](NC1)C)N1C=CC=N1 NNOMIHHWHPPSAI-SSPJITILSA-N 0.000 claims 1
- NUUUULZSGGTOOQ-GFCCVEGCSA-N 1-(6-chloro-3,3-dimethyl-2h-indol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C(C)(C)C1 NUUUULZSGGTOOQ-GFCCVEGCSA-N 0.000 claims 1
- GRJCVQPSSBRDFC-AWRNFGRUSA-N 1-(6-chloro-3-ethyl-3-methyl-2h-indol-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C12=CC(Cl)=CC=C2C(CC)(C)CN1C(=O)CN1C[C@@H](C)NC[C@@H]1COC GRJCVQPSSBRDFC-AWRNFGRUSA-N 0.000 claims 1
- GWMDHSZMIZUFBF-BTQNPOSSSA-N 1-(6-chlorospiro[2h-indole-3,1'-cyclobutane]-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C2(CCC2)C1 GWMDHSZMIZUFBF-BTQNPOSSSA-N 0.000 claims 1
- FNGKDPREIQPCPQ-PFEQFJNWSA-N 1-(6-chlorospiro[2h-indole-3,1'-cyclopentane]-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C2(CCCC2)C1 FNGKDPREIQPCPQ-PFEQFJNWSA-N 0.000 claims 1
- LEPFHBUBBUEPEU-UTONKHPSSA-N 1-(6-chlorospiro[2h-indole-3,1'-cyclopropane]-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C2(CC2)C1 LEPFHBUBBUEPEU-UTONKHPSSA-N 0.000 claims 1
- OSFKLOHBDVTAAB-WGMYLSDTSA-N 1-(6-cyclohexyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C3CCCCC3)=NC=C2C(C)(C)C1 OSFKLOHBDVTAAB-WGMYLSDTSA-N 0.000 claims 1
- MMHDGVDOEOLCMI-SJLPKXTDSA-N 1-(6-cyclopentyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C3CCCC3)=NC=C2C(C)(C)C1 MMHDGVDOEOLCMI-SJLPKXTDSA-N 0.000 claims 1
- XINPIEVBQSNFRD-UWGSCQAASA-N 1-(6-ethylsulfonyl-3,3-dimethyl-2h-indol-1-yl)-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C=1C(S(=O)(=O)CC)=CC=C(C(C2)(C)C)C=1N2C(=O)CN1C[C@@H](C)NC[C@@H]1COC XINPIEVBQSNFRD-UWGSCQAASA-N 0.000 claims 1
- JYRMPJWEDYIOOQ-LLVKDONJSA-N 1-(6-fluoro-2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(F)=CC=C2CC1 JYRMPJWEDYIOOQ-LLVKDONJSA-N 0.000 claims 1
- AZZBQNKRRWVSFT-GFCCVEGCSA-N 1-(6-methoxy-2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C12=CC(OC)=CC=C2CCN1C(=O)CN1CCN[C@H](C)C1 AZZBQNKRRWVSFT-GFCCVEGCSA-N 0.000 claims 1
- OHNGWVZUUYBPTF-CYBMUJFWSA-N 1-(6-methyl-2,3-dihydroindol-1-yl)-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(C)=CC=C2CC1 OHNGWVZUUYBPTF-CYBMUJFWSA-N 0.000 claims 1
- IWEWROOCBZADIK-NVWGRRAGSA-N 1-[(3r)-6-benzyl-3-methyl-3-(3-methyl-1,2-oxazol-5-yl)-2h-indol-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CC=C2[C@@](C)(C=2ON=C(C)C=2)C1 IWEWROOCBZADIK-NVWGRRAGSA-N 0.000 claims 1
- JRCNDDLVDCWNDB-QNDYNBFSSA-N 1-[(3r)-6-bromo-3-(methoxymethyl)-3-methyl-2h-indol-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Br)=CC=C2[C@@](C)(COC)C1 JRCNDDLVDCWNDB-QNDYNBFSSA-N 0.000 claims 1
- IWEWROOCBZADIK-HPPHPRJYSA-N 1-[(3s)-6-benzyl-3-methyl-3-(3-methyl-1,2-oxazol-5-yl)-2h-indol-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CC=C2[C@](C)(C=2ON=C(C)C=2)C1 IWEWROOCBZADIK-HPPHPRJYSA-N 0.000 claims 1
- JRCNDDLVDCWNDB-XLTSPECSSA-N 1-[(3s)-6-bromo-3-(methoxymethyl)-3-methyl-2h-indol-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Br)=CC=C2[C@](C)(COC)C1 JRCNDDLVDCWNDB-XLTSPECSSA-N 0.000 claims 1
- JNDLERHHAQJWMF-HZPDHXFCSA-N 1-[1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-6-yl]pyrrolidin-2-one Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(N3C(CCC3)=O)=NC=C2C(C)(C)C1 JNDLERHHAQJWMF-HZPDHXFCSA-N 0.000 claims 1
- ZYWNTIVOMFMRMA-NVXWUHKLSA-N 1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3,3,5-trimethyl-2h-indole-6-carbonitrile Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C#N)=C(C)C=C2C(C)(C)C1 ZYWNTIVOMFMRMA-NVXWUHKLSA-N 0.000 claims 1
- ZVXNSMKQOGWXQC-DTPOWOMPSA-N 1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3,3,6-trimethyl-2h-pyrrolo[2,3-c]pyridin-5-one;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CN(C)C(=O)C=C2C(C)(C)C1 ZVXNSMKQOGWXQC-DTPOWOMPSA-N 0.000 claims 1
- AIBFJGJDHOUVDI-VNYZMKMESA-N 1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3,3-dimethyl-2h-indole-6-carbonitrile;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C#N)=CC=C2C(C)(C)C1 AIBFJGJDHOUVDI-VNYZMKMESA-N 0.000 claims 1
- TYTCNHSGTFZJGR-UKRRQHHQSA-N 1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridine-6-carbonitrile Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C#N)=NC=C2C(C)(C)C1 TYTCNHSGTFZJGR-UKRRQHHQSA-N 0.000 claims 1
- DGBPPAQMRSTHMK-GBNZRNLASA-N 1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3,3-dimethyl-6-(2-methylpropyl)-2h-pyrrolo[2,3-c]pyridin-5-one;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CN(CC(C)C)C(=O)C=C2C(C)(C)C1 DGBPPAQMRSTHMK-GBNZRNLASA-N 0.000 claims 1
- DYXVCQMOKHZKMO-LCHCQGBESA-N 1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3-methyl-3-phenyl-2h-indole-6-carbonitrile Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C#N)=CC=C2C(C)(C=2C=CC=CC=2)C1 DYXVCQMOKHZKMO-LCHCQGBESA-N 0.000 claims 1
- IRBACIDTTCIGAP-TZTBQANOSA-N 1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3-methyl-3-pyridin-2-yl-2h-indole-6-carbonitrile;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C#N)=CC=C2C(C)(C=2N=CC=CC=2)C1 IRBACIDTTCIGAP-TZTBQANOSA-N 0.000 claims 1
- XYKQQBINQQWGPR-FXKISCCRSA-N 1-[3,3-dimethyl-6-(1-methylpyrazol-4-yl)-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C3=CN(C)N=C3)=NC=C2C(C)(C)C1 XYKQQBINQQWGPR-FXKISCCRSA-N 0.000 claims 1
- FHCRKPLVSYTYPQ-WIYYLYMNSA-N 1-[3,3-dimethyl-6-(1-phenylethenyl)-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C(=C)C=3C=CC=CC=3)=NC=C2C(C)(C)C1 FHCRKPLVSYTYPQ-WIYYLYMNSA-N 0.000 claims 1
- IHGCICJEOROZAH-MBYSJIBESA-N 1-[3,3-dimethyl-6-(1-phenylethyl)-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C(C)C=3C=CC=CC=3)=NC=C2C(C)(C)C1 IHGCICJEOROZAH-MBYSJIBESA-N 0.000 claims 1
- NDDCFJFBGJZMKX-STYNFMPRSA-N 1-[3,3-dimethyl-6-(2-methylphenoxy)-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(OC=3C(=CC=CC=3)C)=NC=C2C(C)(C)C1 NDDCFJFBGJZMKX-STYNFMPRSA-N 0.000 claims 1
- MIGMYZOQSOKYEJ-SJLPKXTDSA-N 1-[3,3-dimethyl-6-(2-methylpropyl)-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC(C)C)=NC=C2C(C)(C)C1 MIGMYZOQSOKYEJ-SJLPKXTDSA-N 0.000 claims 1
- DRFZHLJNZOUPNP-RKDOVGOJSA-N 1-[3,3-dimethyl-6-(2-methylpropylsulfonyl)-2h-indol-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)CC(C)C)=CC=C2C(C)(C)C1 DRFZHLJNZOUPNP-RKDOVGOJSA-N 0.000 claims 1
- IUFXQTSSUNFBHV-SWYZXDRTSA-N 1-[3,3-dimethyl-6-(2h-tetrazol-5-yl)-2h-indol-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C=3NN=NN=3)=CC=C2C(C)(C)C1 IUFXQTSSUNFBHV-SWYZXDRTSA-N 0.000 claims 1
- SFRBIHGATTUURB-IEBWSBKVSA-N 1-[3,3-dimethyl-6-(3-methylbutyl)-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CCC(C)C)=NC=C2C(C)(C)C1 SFRBIHGATTUURB-IEBWSBKVSA-N 0.000 claims 1
- SZRZWBPLJRJDOU-FXKISCCRSA-N 1-[3,3-dimethyl-6-(5-methylthiophen-2-yl)-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C=3SC(C)=CC=3)=NC=C2C(C)(C)C1 SZRZWBPLJRJDOU-FXKISCCRSA-N 0.000 claims 1
- UUTFEPWRLKUUAF-OVAHNPOGSA-N 1-[3,3-dimethyl-6-(n-methylanilino)-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(N(C)C=3C=CC=CC=3)=NC=C2C(C)(C)C1 UUTFEPWRLKUUAF-OVAHNPOGSA-N 0.000 claims 1
- PKNQQBIEUREYIR-AEFFLSMTSA-N 1-[3,3-dimethyl-6-(pyrazol-1-ylmethyl)-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2s,5r)-2-ethyl-5-methylpiperazin-1-yl]ethanone Chemical compound CC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CN3N=CC=C3)=NC=C2C(C)(C)C1 PKNQQBIEUREYIR-AEFFLSMTSA-N 0.000 claims 1
- GYMICEJGTKAHQW-RKDOVGOJSA-N 1-[5-fluoro-6-(4-methoxyphenyl)sulfonyl-3,3-dimethyl-2h-indol-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C=3C=CC(OC)=CC=3)=C(F)C=C2C(C)(C)C1 GYMICEJGTKAHQW-RKDOVGOJSA-N 0.000 claims 1
- LFRGOURLHKRMND-TZIWHRDSSA-N 1-[6-(1,1-difluoro-3-methylbutyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone Chemical compound C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C(C(C1)(C)C)=NC=C(C=2)C(F)(F)CC(C)C)N1CCOCC1 LFRGOURLHKRMND-TZIWHRDSSA-N 0.000 claims 1
- QRWDEUIVLJUMDY-GZJHNZOKSA-N 1-[6-(1,1-difluoro-3-methylbutyl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C=C(N=CC=2C(C)(C)C1)C(F)(F)CC(C)C)N1CCOCC1 QRWDEUIVLJUMDY-GZJHNZOKSA-N 0.000 claims 1
- PPDFTAMDNLSQOJ-DWNZUMETSA-N 1-[6-(1,1-difluorobutyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-ethylmorpholin-4-yl]methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C(C(C1)(C)C)=NC=C(C=2)C(F)(F)CCC)N1CCOC[C@H]1CC PPDFTAMDNLSQOJ-DWNZUMETSA-N 0.000 claims 1
- OAYYAIQOSSPJRD-YGJXXQMASA-N 1-[6-(1,1-difluorobutyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-fluoropyrrolidin-1-yl]methyl]-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C(C(C1)(C)C)=NC=C(C=2)C(F)(F)CCC)N1CC[C@@H](F)C1 OAYYAIQOSSPJRD-YGJXXQMASA-N 0.000 claims 1
- POIUVYPSBMLQNV-OVAHNPOGSA-N 1-[6-(1,1-difluorobutyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C(C(C1)(C)C)=NC=C(C=2)C(F)(F)CCC)N1CCOCC1 POIUVYPSBMLQNV-OVAHNPOGSA-N 0.000 claims 1
- RJCAXUGFMPASEB-DJPUBCJQSA-N 1-[6-(1,1-difluorobutyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[[(3r)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C(C(C1)(C)C)=NC=C(C=2)C(F)(F)CCC)N1CCOC[C@H]1C RJCAXUGFMPASEB-DJPUBCJQSA-N 0.000 claims 1
- ATRMCIRAEJZIIH-STYNFMPRSA-N 1-[6-(1,1-difluorobutyl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C=C(N=CC=2C(C)(C)C1)C(F)(F)CCC)N1CCOCC1 ATRMCIRAEJZIIH-STYNFMPRSA-N 0.000 claims 1
- VNOBJGNRBJZETN-OYRDCCEQSA-N 1-[6-(1,1-difluorobutyl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[[(3r)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C=C(N=CC=2C(C)(C)C1)C(F)(F)CCC)N1CCOC[C@H]1C VNOBJGNRBJZETN-OYRDCCEQSA-N 0.000 claims 1
- INGDFJLYMANJGK-PPPUBMIESA-N 1-[6-(1,1-difluorobutyl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2s,5r)-5-methyl-2-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C=C(N=CC=2C(C)(C)C1)C(F)(F)CCC)C1=NC=CS1 INGDFJLYMANJGK-PPPUBMIESA-N 0.000 claims 1
- BABYKIFDPATSNR-FDCKWBIYSA-N 1-[6-(1,1-difluoroethyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-(2,3-dihydropyrrolo[2,3-b]pyridin-1-ylmethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C1CC2=CC=CN=C2N1C[C@@H]1N(CC(=O)N2C3=CC(=CN=C3C(C)(C)C2)C(C)(F)F)C[C@@H](C)NC1 BABYKIFDPATSNR-FDCKWBIYSA-N 0.000 claims 1
- QZFCFASFVINCKE-MUMAJMNHSA-N 1-[6-(1,1-difluoroethyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-ethylmorpholin-4-yl]methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.CC[C@@H]1COCCN1C[C@@H]1N(CC(=O)N2C3=CC(=CN=C3C(C)(C)C2)C(C)(F)F)C[C@@H](C)NC1 QZFCFASFVINCKE-MUMAJMNHSA-N 0.000 claims 1
- ANRFURQKWUSPRQ-KFWOVWKUSA-N 1-[6-(1,1-difluoroethyl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C(C)(F)F)=NC=C2C(C)(C)C1 ANRFURQKWUSPRQ-KFWOVWKUSA-N 0.000 claims 1
- JDDHJQQVOCRPCF-MQOQIFBVSA-N 1-[6-(1,1-difluoropropyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-(methoxymethyl)morpholin-4-yl]methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C(C(C1)(C)C)=NC=C(C=2)C(F)(F)CC)N1CCOC[C@H]1COC JDDHJQQVOCRPCF-MQOQIFBVSA-N 0.000 claims 1
- SENVFRJGPXWCTF-MQOQIFBVSA-N 1-[6-(1,1-difluoropropyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-ethylmorpholin-4-yl]methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.CC[C@@H]1COCCN1C[C@@H]1N(CC(=O)N2C3=CC(=CN=C3C(C)(C)C2)C(F)(F)CC)C[C@@H](C)NC1 SENVFRJGPXWCTF-MQOQIFBVSA-N 0.000 claims 1
- WELLXEFFJBHYTK-IIUXMCBISA-N 1-[6-(1,1-difluoropropyl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-fluoropyrrolidin-1-yl]methyl]-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C=C(N=CC=2C(C)(C)C1)C(F)(F)CC)N1CC[C@@H](F)C1 WELLXEFFJBHYTK-IIUXMCBISA-N 0.000 claims 1
- JEUZUWLNYNMTLO-QNBGGDODSA-N 1-[6-(2,6-difluorophenoxy)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(OC=3C(=CC=CC=3F)F)=NC=C2C(C)(C)C1 JEUZUWLNYNMTLO-QNBGGDODSA-N 0.000 claims 1
- CTZFUWBWEIWXGF-GZJHNZOKSA-N 1-[6-(2,6-dimethylphenoxy)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(OC=3C(=CC=CC=3C)C)=NC=C2C(C)(C)C1 CTZFUWBWEIWXGF-GZJHNZOKSA-N 0.000 claims 1
- QCEHUVDBDHXQKW-JAXOOIEVSA-N 1-[6-(2-chloro-6-methylphenoxy)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(OC=3C(=CC=CC=3C)Cl)=NC=C2C(C)(C)C1 QCEHUVDBDHXQKW-JAXOOIEVSA-N 0.000 claims 1
- UGVZBKHYYVSBFX-IAGOWNOFSA-N 1-[6-(2-chlorophenoxy)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(OC=3C(=CC=CC=3)Cl)=NC=C2C(C)(C)C1 UGVZBKHYYVSBFX-IAGOWNOFSA-N 0.000 claims 1
- QXEGZENVBFMOIW-POCMBTLOSA-N 1-[6-(2-chlorophenoxy)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-[(4-fluoropyrazol-1-yl)methyl]-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2N=CC(F)=C2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2OC1=CC=CC=C1Cl QXEGZENVBFMOIW-POCMBTLOSA-N 0.000 claims 1
- PPAMQBLWNMNPNU-VMJMSTHCSA-N 1-[6-(2-chlorophenoxy)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1C(=O)N2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2OC1=CC=CC=C1Cl PPAMQBLWNMNPNU-VMJMSTHCSA-N 0.000 claims 1
- ALHNEHVEBWDBDZ-OSBWNOESSA-N 1-[6-(2-cyclopropyl-1,1-difluoroethyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2C(F)(F)CC1CC1 ALHNEHVEBWDBDZ-OSBWNOESSA-N 0.000 claims 1
- AKLJTECFHWYMTJ-BTQNPOSSSA-N 1-[6-(5-chloro-2-fluorophenyl)-2,3-dihydropyrrolo[3,2-c]pyridin-1-yl]-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(C=3C(=CC=C(Cl)C=3)F)=NC=C2CC1 AKLJTECFHWYMTJ-BTQNPOSSSA-N 0.000 claims 1
- AOCBRYIXXQEDIB-PKLMIRHRSA-N 1-[6-(benzenesulfonyl)-2,3-dihydroindol-1-yl]-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C=3C=CC=CC=3)=CC=C2CC1 AOCBRYIXXQEDIB-PKLMIRHRSA-N 0.000 claims 1
- BDIDZWNQFXKGTO-UNTBIKODSA-N 1-[6-(benzenesulfonyl)-3,3-dimethyl-2h-indol-1-yl]-2-[(3r)-3-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C=3C=CC=CC=3)=CC=C2C(C)(C)C1 BDIDZWNQFXKGTO-UNTBIKODSA-N 0.000 claims 1
- YITQBRGWZXHXCK-OAHLLOKOSA-N 1-[6-(benzenesulfonyl)-5-fluoro-2,3-dihydroindol-1-yl]-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C=3C=CC=CC=3)=C(F)C=C2CC1 YITQBRGWZXHXCK-OAHLLOKOSA-N 0.000 claims 1
- MFJFUDRAHIYFPO-WCRQIBMVSA-N 1-[6-(benzenesulfonyl)-5-fluoro-3,3-dimethyl-2h-indol-1-yl]-2-[(2s,5r)-2-ethyl-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.CC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C=3C=CC=CC=3)=C(F)C=C2C(C)(C)C1 MFJFUDRAHIYFPO-WCRQIBMVSA-N 0.000 claims 1
- DJCYGVLLUPYKLN-IEBWSBKVSA-N 1-[6-(cyclohexen-1-yl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C=3CCCCC=3)=NC=C2C(C)(C)C1 DJCYGVLLUPYKLN-IEBWSBKVSA-N 0.000 claims 1
- YDOOULBWFWNWCG-WIYYLYMNSA-N 1-[6-(cyclohexylmethyl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC3CCCCC3)=NC=C2C(C)(C)C1 YDOOULBWFWNWCG-WIYYLYMNSA-N 0.000 claims 1
- DPNPROJIWHGNIQ-SJLPKXTDSA-N 1-[6-(cyclopenten-1-yl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C=3CCCC=3)=NC=C2C(C)(C)C1 DPNPROJIWHGNIQ-SJLPKXTDSA-N 0.000 claims 1
- RFUDBILKSNNHSU-FXKISCCRSA-N 1-[6-(furan-3-yl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C3=COC=C3)=NC=C2C(C)(C)C1 RFUDBILKSNNHSU-FXKISCCRSA-N 0.000 claims 1
- MBXBHLPEPUDDGO-UNTBIKODSA-N 1-[6-(n-methylanilino)-2,3-dihydroindol-1-yl]-2-[(3r)-3-methylpiperazin-1-yl]ethanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1CN[C@H](C)CN1CC(=O)N1C2=CC(N(C)C=3C=CC=CC=3)=CC=C2CC1 MBXBHLPEPUDDGO-UNTBIKODSA-N 0.000 claims 1
- NTZHNAMTKFMUEN-RBEQJIRESA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-fluoropyrrolidin-1-yl]methyl]-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C[C@H](F)CC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1F NTZHNAMTKFMUEN-RBEQJIRESA-N 0.000 claims 1
- IZHRTRGLYAIYMI-LSGPWKTQSA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-[[(3s)-3-fluoropyrrolidin-1-yl]methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C[C@@H](F)CC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1F IZHRTRGLYAIYMI-LSGPWKTQSA-N 0.000 claims 1
- LQFYYXISAPXVHR-CHOFETAFSA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1F LQFYYXISAPXVHR-CHOFETAFSA-N 0.000 claims 1
- VJDXXKHSIAQLSH-TULDICIXSA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[[(3r)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2[C@@H](COCC2)C)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1F VJDXXKHSIAQLSH-TULDICIXSA-N 0.000 claims 1
- YUAYQROLLICMPM-OXQOHEQNSA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C(=CC(F)=CC=3)F)=NC=C2C(C)(C)C1 YUAYQROLLICMPM-OXQOHEQNSA-N 0.000 claims 1
- TYTLQEUXRFDNTO-VMJMSTHCSA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-[(3,3-difluoropyrrolidin-1-yl)methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2CC(F)(F)CC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F TYTLQEUXRFDNTO-VMJMSTHCSA-N 0.000 claims 1
- AVDSALWLQZMVDA-RPQSWWTGSA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-[(3,5-dimethyl-1,2,4-triazol-1-yl)methyl]-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(=NC(C)=N2)C)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F AVDSALWLQZMVDA-RPQSWWTGSA-N 0.000 claims 1
- NWHFILLWDFFISM-ULKDTRLFSA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-fluoropyrrolidin-1-yl]methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C[C@H](F)CC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F NWHFILLWDFFISM-ULKDTRLFSA-N 0.000 claims 1
- NWHFILLWDFFISM-WTJCGIDYSA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-[[(3s)-3-fluoropyrrolidin-1-yl]methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C[C@@H](F)CC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F NWHFILLWDFFISM-WTJCGIDYSA-N 0.000 claims 1
- SQHNMNHBMYWCHU-CHOFETAFSA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F SQHNMNHBMYWCHU-CHOFETAFSA-N 0.000 claims 1
- SINNFFAYEYUNIY-CHOFETAFSA-N 1-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(pyrrolidin-1-ylmethyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2CCCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F SINNFFAYEYUNIY-CHOFETAFSA-N 0.000 claims 1
- KHRUWEIVDXTOHK-OGPPPPIKSA-N 1-[6-[(2-chlorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C(=CC=CC=3)Cl)=NC=C2C(C)(C)C1 KHRUWEIVDXTOHK-OGPPPPIKSA-N 0.000 claims 1
- DLVACKPONOVPTE-GKFBYOHMSA-N 1-[6-[(2-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-fluoropyrrolidin-1-yl]methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C[C@H](F)CC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=CC=C1F DLVACKPONOVPTE-GKFBYOHMSA-N 0.000 claims 1
- IVWUWJOOUGHAQH-LRHYEEQISA-N 1-[6-[(2-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=CC=C1F IVWUWJOOUGHAQH-LRHYEEQISA-N 0.000 claims 1
- RVTQDBSQOFMFRB-LHHRAKGSSA-N 1-[6-[(2-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[[(3r)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2[C@@H](COCC2)C)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=CC=C1F RVTQDBSQOFMFRB-LHHRAKGSSA-N 0.000 claims 1
- HMBHEQGPDBVRRL-YLJYHZDGSA-N 1-[6-[(2-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C(=CC=CC=3)F)=NC=C2C(C)(C)C1 HMBHEQGPDBVRRL-YLJYHZDGSA-N 0.000 claims 1
- CRXACSCPGGFKCE-KFWGXXPESA-N 1-[6-[(2-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1F CRXACSCPGGFKCE-KFWGXXPESA-N 0.000 claims 1
- QELLVSOTOSZBEN-XDRBLFQPSA-N 1-[6-[(2-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[[(3r)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2[C@@H](COCC2)C)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1F QELLVSOTOSZBEN-XDRBLFQPSA-N 0.000 claims 1
- SBSSEUNWSLZLJS-DYESRHJHSA-N 1-[6-[(3-chlorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=C(Cl)C=CC=3)=NC=C2C(C)(C)C1 SBSSEUNWSLZLJS-DYESRHJHSA-N 0.000 claims 1
- RUDSKOYOIRZIFA-DYESRHJHSA-N 1-[6-[(3-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=C(F)C=CC=3)=NC=C2C(C)(C)C1 RUDSKOYOIRZIFA-DYESRHJHSA-N 0.000 claims 1
- ZPHALXCAOPNRSP-DYESRHJHSA-N 1-[6-[(4-chlorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC(Cl)=CC=3)=NC=C2C(C)(C)C1 ZPHALXCAOPNRSP-DYESRHJHSA-N 0.000 claims 1
- KIVYFCYPDQCTHX-NSJVJMCMSA-N 1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-fluoropyrrolidin-1-yl]methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C[C@H](F)CC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1 KIVYFCYPDQCTHX-NSJVJMCMSA-N 0.000 claims 1
- YKPGNOATFOHTMM-OYNPXDHBSA-N 1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1 YKPGNOATFOHTMM-OYNPXDHBSA-N 0.000 claims 1
- DZRJSEYGTUSLSV-FBLZNNLISA-N 1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[[(3r)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2[C@@H](COCC2)C)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1 DZRJSEYGTUSLSV-FBLZNNLISA-N 0.000 claims 1
- RBLFGUVVSYPKSV-VXBHWDOESA-N 1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[[(3r)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2[C@@H](COCC2)C)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1 RBLFGUVVSYPKSV-VXBHWDOESA-N 0.000 claims 1
- DZRJSEYGTUSLSV-PWMWVSTOSA-N 1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[[(3s)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2[C@H](COCC2)C)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1 DZRJSEYGTUSLSV-PWMWVSTOSA-N 0.000 claims 1
- QRILDYVZZITLEI-MRXNPFEDSA-N 1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(3r)-3-methylpiperazin-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC(F)=CC=3)=CN=C2C(C)(C)C1 QRILDYVZZITLEI-MRXNPFEDSA-N 0.000 claims 1
- YLDGFNCVGFINFZ-DYESRHJHSA-N 1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC(F)=CC=3)=NC=C2C(C)(C)C1 YLDGFNCVGFINFZ-DYESRHJHSA-N 0.000 claims 1
- KEJHVMOZKGMJFU-OSMGBBKRSA-N 1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1 KEJHVMOZKGMJFU-OSMGBBKRSA-N 0.000 claims 1
- IXJSTGQJTSBEKP-FBLZNNLISA-N 1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[[(3r)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2[C@@H](COCC2)C)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1 IXJSTGQJTSBEKP-FBLZNNLISA-N 0.000 claims 1
- SOURDDXEVPWYFO-GKFBYOHMSA-N 1-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-2-[[(3r)-3-fluoropyrrolidin-1-yl]methyl]-5-methylpiperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C[C@H](F)CC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2C(F)(F)C1=CC=CC=C1 SOURDDXEVPWYFO-GKFBYOHMSA-N 0.000 claims 1
- YVTNYEHCLUANGE-LRHYEEQISA-N 1-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2C(F)(F)C1=CC=CC=C1 YVTNYEHCLUANGE-LRHYEEQISA-N 0.000 claims 1
- QDWXQGSVXWJKEH-POCMBTLOSA-N 1-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C(F)(F)C=3C=CC=CC=3)=NC=C2C(C)(C)C1 QDWXQGSVXWJKEH-POCMBTLOSA-N 0.000 claims 1
- AJVJLHMNPAEBAT-IUFJOMBNSA-N 1-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-2-[(4-fluoropyrazol-1-yl)methyl]-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2N=CC(F)=C2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2C(F)(F)C1=CC=CC=C1 AJVJLHMNPAEBAT-IUFJOMBNSA-N 0.000 claims 1
- QRBYJAFQWGLJDB-HRXPAQHTSA-N 1-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholin-4-ylmethyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2C(F)(F)C1=CC=CC=C1 QRBYJAFQWGLJDB-HRXPAQHTSA-N 0.000 claims 1
- XFJKHBJWLZSHSE-CHOFETAFSA-N 1-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1C(=O)N2CCOCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2C(F)(F)C1=CC=CC=C1 XFJKHBJWLZSHSE-CHOFETAFSA-N 0.000 claims 1
- VCOVGHNOWSTZIO-HRXPAQHTSA-N 1-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-[(2r,5r)-5-methyl-2-[(4-methylpyrazol-1-yl)methyl]piperazin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2N=CC(C)=C2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2C(F)(F)C1=CC=CC=C1 VCOVGHNOWSTZIO-HRXPAQHTSA-N 0.000 claims 1
- JRCNDDLVDCWNDB-AWRNFGRUSA-N 1-[6-bromo-3-(methoxymethyl)-3-methyl-2h-indol-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Br)=CC=C2C(C)(COC)C1 JRCNDDLVDCWNDB-AWRNFGRUSA-N 0.000 claims 1
- DOIDMZYZVQDNOP-UKRRQHHQSA-N 1-[6-chloro-3,3-dimethyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-2h-indol-1-yl]-2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=C(C=3ON=C(C)N=3)C=C2C(C)(C)C1 DOIDMZYZVQDNOP-UKRRQHHQSA-N 0.000 claims 1
- NYGHOXAPEWAWQB-WYWDDXCHSA-N 1-[[(2r,5r)-1-[2-(6-benzoyl-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl)-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2C(=O)C1=CC=CC=C1 NYGHOXAPEWAWQB-WYWDDXCHSA-N 0.000 claims 1
- PBTLYAYBDAUUKI-LRHYEEQISA-N 1-[[(2r,5r)-1-[2-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl)-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=CC=C1 PBTLYAYBDAUUKI-LRHYEEQISA-N 0.000 claims 1
- VKRRLORPSBNZGU-LRHYEEQISA-N 1-[[(2r,5r)-1-[2-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1 VKRRLORPSBNZGU-LRHYEEQISA-N 0.000 claims 1
- SBDRTKCWOKUULH-AYCGRUCCSA-N 1-[[(2r,5r)-1-[2-[3-[(2,4-difluorophenyl)methyl]-7,7-dimethyl-6h-pyrrolo[3,2-c]pyridazin-5-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NN=C2CC1=CC=C(F)C=C1F SBDRTKCWOKUULH-AYCGRUCCSA-N 0.000 claims 1
- GTAOBAOFISGLEL-JAXOOIEVSA-N 1-[[(2r,5r)-1-[2-[6-(1,1-difluoro-2-methylpropyl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C=C(N=CC=2C(C)(C)C1)C(F)(F)C(C)C)N1CCCC1=O GTAOBAOFISGLEL-JAXOOIEVSA-N 0.000 claims 1
- HBNLNGITCUAYJA-FOKFTXDMSA-N 1-[[(2r,5r)-1-[2-[6-(1,1-difluoro-3-methylbutyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C(C(C1)(C)C)=NC=C(C=2)C(F)(F)CC(C)C)N1CCCC1=O HBNLNGITCUAYJA-FOKFTXDMSA-N 0.000 claims 1
- MLZDDEVXKSAKQX-STYNFMPRSA-N 1-[[(2r,5r)-1-[2-[6-(1,1-difluoro-3-methylbutyl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C=C(N=CC=2C(C)(C)C1)C(F)(F)CC(C)C)N1CCCC1=O MLZDDEVXKSAKQX-STYNFMPRSA-N 0.000 claims 1
- ZOIHEBWCPKONTI-POCMBTLOSA-N 1-[[(2r,5r)-1-[2-[6-(1,1-difluorobutyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C(C(C1)(C)C)=NC=C(C=2)C(F)(F)CCC)N1CCCC1=O ZOIHEBWCPKONTI-POCMBTLOSA-N 0.000 claims 1
- NSYFGPCDSJOBMT-JAXOOIEVSA-N 1-[[(2r,5r)-1-[2-[6-(1,1-difluorobutyl)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C=C(N=CC=2C(C)(C)C1)C(F)(F)CCC)N1CCCC1=O NSYFGPCDSJOBMT-JAXOOIEVSA-N 0.000 claims 1
- CYTYYEVOUUZJNR-FXKISCCRSA-N 1-[[(2r,5r)-1-[2-[6-(1,1-difluoroethyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@@H]1N(CC(=O)N2C3=CC(=CN=C3C(C)(C)C2)C(C)(F)F)C[C@H](NC1)C)N1CCCC1=O CYTYYEVOUUZJNR-FXKISCCRSA-N 0.000 claims 1
- QGASBYBIHYJPEW-PHJLCXHGSA-N 1-[[(2r,5r)-1-[2-[6-(1,1-difluoropropyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H]1CN[C@H](C)CN1CC(=O)N1C=2C(C(C1)(C)C)=NC=C(C=2)C(F)(F)CC)N1CCCC1=O QGASBYBIHYJPEW-PHJLCXHGSA-N 0.000 claims 1
- OGJBVQXDQCYXBK-STYNFMPRSA-N 1-[[(2r,5r)-1-[2-[6-(2-chlorophenoxy)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2OC1=CC=CC=C1Cl OGJBVQXDQCYXBK-STYNFMPRSA-N 0.000 claims 1
- RGVUEYWRPDILAT-YLJYHZDGSA-N 1-[[(2r,5r)-1-[2-[6-(2-cyclopropyl-1,1-difluoroethyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one Chemical compound C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2C(F)(F)CC1CC1 RGVUEYWRPDILAT-YLJYHZDGSA-N 0.000 claims 1
- QOBCQNPVFFATBN-VMJMSTHCSA-N 1-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1F QOBCQNPVFFATBN-VMJMSTHCSA-N 0.000 claims 1
- FGWBBLBMJIKECC-AQHBPOCSSA-N 1-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]piperidin-2-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(CCCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F FGWBBLBMJIKECC-AQHBPOCSSA-N 0.000 claims 1
- UGGGFCKBUDMDSD-VMJMSTHCSA-N 1-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrazin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(C=NC=C2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F UGGGFCKBUDMDSD-VMJMSTHCSA-N 0.000 claims 1
- VXHMNLFIOKDGMN-CHOFETAFSA-N 1-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyridin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(C=CC=C2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F VXHMNLFIOKDGMN-CHOFETAFSA-N 0.000 claims 1
- APTRVTGBURHSQO-VMJMSTHCSA-N 1-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrimidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(N=CC=C2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F APTRVTGBURHSQO-VMJMSTHCSA-N 0.000 claims 1
- SYVKQFPMGAXYGR-TVNLMDKXSA-N 1-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F SYVKQFPMGAXYGR-TVNLMDKXSA-N 0.000 claims 1
- CFDQOBGFTMLXQJ-VMJMSTHCSA-N 1-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-3-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2CC(=O)CC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F CFDQOBGFTMLXQJ-VMJMSTHCSA-N 0.000 claims 1
- GAUYJNDTRJAFJX-JENXBZAWSA-N 1-[[(2r,5r)-1-[2-[6-[(2-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=CC=C1F GAUYJNDTRJAFJX-JENXBZAWSA-N 0.000 claims 1
- JYPSRINJKYHWIF-JENXBZAWSA-N 1-[[(2r,5r)-1-[2-[6-[(2-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1F JYPSRINJKYHWIF-JENXBZAWSA-N 0.000 claims 1
- PMZNVVDJEHZILZ-CHOFETAFSA-N 1-[[(2r,5r)-1-[2-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1 PMZNVVDJEHZILZ-CHOFETAFSA-N 0.000 claims 1
- AOZDMGHEQDCQAE-PHJLCXHGSA-N 1-[[(2r,5r)-1-[2-[6-[cyclopropyl(difluoro)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2C(F)(F)C1CC1 AOZDMGHEQDCQAE-PHJLCXHGSA-N 0.000 claims 1
- QDHJKLDGIRGOQP-JENXBZAWSA-N 1-[[(2r,5r)-1-[2-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2C(F)(F)C1=CC=CC=C1 QDHJKLDGIRGOQP-JENXBZAWSA-N 0.000 claims 1
- QYHCVWPZHDEUJZ-GNGUGDOWSA-N 1-[[(2r,5r)-1-[2-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]-3-methylimidazolidin-2-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(N(C)CC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2C(F)(F)C1=CC=CC=C1 QYHCVWPZHDEUJZ-GNGUGDOWSA-N 0.000 claims 1
- CMJAFKZFVDPYQG-YYMFTFNESA-N 1-[[(2r,5r)-1-[2-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(CCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2C(F)(F)C1=CC=CC=C1 CMJAFKZFVDPYQG-YYMFTFNESA-N 0.000 claims 1
- KNXSAKLOCDOKQV-FOKFTXDMSA-N 1-[[(2r,5r)-1-[2-[6-[difluoro(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyrrolidine-2,5-dione;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(CCC2=O)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2C(F)(F)C1=CC=CC=C1 KNXSAKLOCDOKQV-FOKFTXDMSA-N 0.000 claims 1
- OZWNYFADIYDIMC-POCMBTLOSA-N 1-[[1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3,3-dimethyl-2h-indol-6-yl]methyl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CN3C(CCC3)=O)=CC=C2C(C)(C)C1 OZWNYFADIYDIMC-POCMBTLOSA-N 0.000 claims 1
- ZOWCZSATKAMVAJ-NTKDMRAZSA-N 2-[(2r,5r)-2-(azetidine-1-carbonyl)-5-methylpiperazin-1-yl]-1-(6-benzyl-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl)ethanone Chemical compound C([C@H](NC[C@@H]1C(=O)N2CCC2)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=CC=C1 ZOWCZSATKAMVAJ-NTKDMRAZSA-N 0.000 claims 1
- ORJAOIJIYHRTCD-WIYYLYMNSA-N 2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]-1-[6-[(3-methoxyphenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=C(OC)C=CC=3)=NC=C2C(C)(C)C1 ORJAOIJIYHRTCD-WIYYLYMNSA-N 0.000 claims 1
- ITZFVKSFCUBFLE-WIYYLYMNSA-N 2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]-1-[6-[(4-methoxyphenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]ethanone Chemical compound COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC(OC)=CC=3)=NC=C2C(C)(C)C1 ITZFVKSFCUBFLE-WIYYLYMNSA-N 0.000 claims 1
- KMROQSVWXXZBDU-WQLZUNPQSA-N 2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]-1-[6-[methoxy(phenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(C(OC)C=3C=CC=CC=3)=NC=C2C(C)(C)C1 KMROQSVWXXZBDU-WQLZUNPQSA-N 0.000 claims 1
- MCCSVYKFTQUXPE-MCFLWNBJSA-N 2-[(2r,5r)-2-[[(3r)-3-ethylmorpholin-4-yl]methyl]-5-methylpiperazin-1-yl]-1-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.CC[C@@H]1COCCN1C[C@@H]1N(CC(=O)N2C3=CC(CC=4C=CC(F)=CC=4)=CN=C3C(C)(C)C2)C[C@@H](C)NC1 MCCSVYKFTQUXPE-MCFLWNBJSA-N 0.000 claims 1
- MDYYHBCZGFQUME-UTONKHPSSA-N 2-[(3r)-3-methylpiperazin-1-yl]-1-(6-methylsulfonyl-2,3-dihydroindol-1-yl)ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(S(C)(=O)=O)=CC=C2CC1 MDYYHBCZGFQUME-UTONKHPSSA-N 0.000 claims 1
- RTMLXSAEKOYYRI-CQSZACIVSA-N 2-[(3r)-3-methylpiperazin-1-yl]-1-(6-propan-2-yl-2,3-dihydroindol-1-yl)ethanone Chemical compound C12=CC(C(C)C)=CC=C2CCN1C(=O)CN1CCN[C@H](C)C1 RTMLXSAEKOYYRI-CQSZACIVSA-N 0.000 claims 1
- JWUVMYRHUBPIKO-XFULWGLBSA-N 2-[(3r)-3-methylpiperazin-1-yl]-1-(6-pyrrolidin-1-ylsulfonyl-2,3-dihydroindol-1-yl)ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)N3CCCC3)=CC=C2CC1 JWUVMYRHUBPIKO-XFULWGLBSA-N 0.000 claims 1
- DIIPVDDVRIYCOF-OAHLLOKOSA-N 2-[(3r)-3-methylpiperazin-1-yl]-1-[6-(pyrrolidine-1-carbonyl)-2,3-dihydroindol-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(C(=O)N3CCCC3)=CC=C2CC1 DIIPVDDVRIYCOF-OAHLLOKOSA-N 0.000 claims 1
- IHAQNABLHANLSX-RFVHGSKJSA-N 2-[(3r)-3-methylpiperazin-1-yl]-1-[6-(trifluoromethoxy)-2,3-dihydroindol-1-yl]ethanone;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(OC(F)(F)F)=CC=C2CC1 IHAQNABLHANLSX-RFVHGSKJSA-N 0.000 claims 1
- BSQRABNHDCTXBE-LLVKDONJSA-N 2-[(3r)-3-methylpiperazin-1-yl]-1-[6-(trifluoromethyl)-2,3-dihydroindol-1-yl]ethanone Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(C(F)(F)F)=CC=C2CC1 BSQRABNHDCTXBE-LLVKDONJSA-N 0.000 claims 1
- HDXCQUCZEAGJNW-VMJMSTHCSA-N 2-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]pyridazin-3-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(C=CC=N2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F HDXCQUCZEAGJNW-VMJMSTHCSA-N 0.000 claims 1
- WWZYCCJZNGEPHX-PBHICJAKSA-N 3,3-dimethyl-1-[(2s)-2-[(3r)-3-methylpiperazin-1-yl]butanoyl]-2h-indole-6-carbonitrile Chemical compound N1([C@@H](CC)C(=O)N2C3=CC(=CC=C3C(C)(C)C2)C#N)CCN[C@H](C)C1 WWZYCCJZNGEPHX-PBHICJAKSA-N 0.000 claims 1
- MWZAENPFBKJOAC-DFQHDRSWSA-N 3,3-dimethyl-1-[(2s)-2-[(3r)-3-methylpiperazin-1-yl]propanoyl]-2h-indole-6-carbonitrile;hydrochloride Chemical compound Cl.N1([C@@H](C)C(=O)N2C3=CC(=CC=C3C(C)(C)C2)C#N)CCN[C@H](C)C1 MWZAENPFBKJOAC-DFQHDRSWSA-N 0.000 claims 1
- YMUDNBGWCFHBEV-CYBMUJFWSA-N 3,3-dimethyl-1-[2-[(3r)-3-methylpiperazin-1-yl]acetyl]-2h-indole-6-carbonitrile Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(C#N)=CC=C2C(C)(C)C1 YMUDNBGWCFHBEV-CYBMUJFWSA-N 0.000 claims 1
- PVXZFPOBUDAVMR-JAXOOIEVSA-N 3-[[(2r,5r)-1-[2-[6-(2-chlorophenoxy)-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]-1,3-oxazolidin-2-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(OCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2OC1=CC=CC=C1Cl PVXZFPOBUDAVMR-JAXOOIEVSA-N 0.000 claims 1
- AZOPEFJEKGPHOQ-UOHPHXQYSA-N 3-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]-1,3-oxazolidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(OCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=NC=C2CC1=CC=C(F)C=C1F AZOPEFJEKGPHOQ-UOHPHXQYSA-N 0.000 claims 1
- HTPNONAKDPBNHH-UOHPHXQYSA-N 3-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]-1,3-oxazolidin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@H](NC[C@@H]1CN2C(OCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F HTPNONAKDPBNHH-UOHPHXQYSA-N 0.000 claims 1
- NCLCKGYUDJTCRV-TVNLMDKXSA-N 3-[[1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-6-yl]methyl]benzonitrile;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=C(C=CC=3)C#N)=NC=C2C(C)(C)C1 NCLCKGYUDJTCRV-TVNLMDKXSA-N 0.000 claims 1
- ASXBCUYMCNASHG-NGASNJAWSA-N 3-methyl-1-[2-[(2r,5r)-5-methyl-2-(morpholine-4-carbonyl)piperazin-1-yl]acetyl]-3-phenyl-2h-indole-6-carbonitrile;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1C(=O)N2CCOCC2)C)N1CC(=O)N(C1=CC(=CC=C11)C#N)CC1(C)C1=CC=CC=C1 ASXBCUYMCNASHG-NGASNJAWSA-N 0.000 claims 1
- FQRQFINXSLBLBV-QIOFEJEBSA-N 3-methyl-1-[2-[(2r,5r)-5-methyl-2-(pyrazol-1-ylmethyl)piperazin-1-yl]acetyl]-3-phenyl-2h-indole-6-carbonitrile;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2N=CC=C2)C)N1CC(=O)N(C1=CC(=CC=C11)C#N)CC1(C)C1=CC=CC=C1 FQRQFINXSLBLBV-QIOFEJEBSA-N 0.000 claims 1
- GCGMYSOYSLVJMX-XMHBETNISA-N 4-[[(2r,5r)-1-[2-[6-(1,1-difluoroethyl)-3,3-dimethyl-2h-pyrrolo[3,2-b]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]-1-methylpiperazin-2-one;dihydrochloride Chemical compound Cl.Cl.C([C@@H]1N(CC(=O)N2C3=CC(=CN=C3C(C)(C)C2)C(C)(F)F)C[C@H](NC1)C)N1CCN(C)C(=O)C1 GCGMYSOYSLVJMX-XMHBETNISA-N 0.000 claims 1
- OQEZIUIRHAFLRQ-TVNLMDKXSA-N 4-[[(2r,5r)-1-[2-[6-[(2,4-difluorophenyl)methyl]-3,3-dimethyl-2h-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]morpholin-3-one;hydrochloride Chemical compound Cl.C([C@H](NC[C@@H]1CN2C(COCC2)=O)C)N1CC(=O)N(C1=C2)CC(C)(C)C1=CN=C2CC1=CC=C(F)C=C1F OQEZIUIRHAFLRQ-TVNLMDKXSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- ZQOKXLBMFRFRSZ-OVAHNPOGSA-N 6-benzyl-1-[2-[(2r,5r)-2-(methoxymethyl)-5-methylpiperazin-1-yl]acetyl]-3,3-dimethyl-2h-pyrrolo[2,3-c]pyridin-5-one;hydrochloride Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CN(CC=3C=CC=CC=3)C(=O)C=C2C(C)(C)C1 ZQOKXLBMFRFRSZ-OVAHNPOGSA-N 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 claims 1
- XJZRJAQVQMWYGW-YPXVDWTCSA-N CCC(C1=CC2=C(C(CN2C(=O)CN3C[C@H](NC[C@@H]3CN4CCOC[C@H]4C)C)(C)C)N=C1)(F)F.Cl Chemical compound CCC(C1=CC2=C(C(CN2C(=O)CN3C[C@H](NC[C@@H]3CN4CCOC[C@H]4C)C)(C)C)N=C1)(F)F.Cl XJZRJAQVQMWYGW-YPXVDWTCSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010039499 Cartilage sarcomas Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- KEBNQXILQHMBAC-UNTBIKODSA-N Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CC=C2CC1 Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CC=C2CC1 KEBNQXILQHMBAC-UNTBIKODSA-N 0.000 claims 1
- DIPZVGKYCVTLME-YRJWVOQCSA-N Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Br)=CC=C2C(C)(C(=O)OC)C1 Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Br)=CC=C2C(C)(C(=O)OC)C1 DIPZVGKYCVTLME-YRJWVOQCSA-N 0.000 claims 1
- WYHUOGNMMDIZER-OSMGBBKRSA-N Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CC=C2C2(CN(C2)C(C)=O)C1 Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(CC=3C=CC=CC=3)=CC=C2C2(CN(C2)C(C)=O)C1 WYHUOGNMMDIZER-OSMGBBKRSA-N 0.000 claims 1
- GJSQLVXHPAUHNE-SATBOSKTSA-N Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C2(CN(C2)C(C)=O)C1 Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C2(CN(C2)C(C)=O)C1 GJSQLVXHPAUHNE-SATBOSKTSA-N 0.000 claims 1
- OBKLGVIIEYEVAJ-OJERSXHUSA-N Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=NC=C2C(C)(C)C1 Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=NC=C2C(C)(C)C1 OBKLGVIIEYEVAJ-OJERSXHUSA-N 0.000 claims 1
- LJNPOUOWVHIATK-JAXOOIEVSA-N Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C=3C=CC=CC=3)=C(F)C=C2C(C)(C)C1 Chemical compound Cl.COC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C=3C=CC=CC=3)=C(F)C=C2C(C)(C)C1 LJNPOUOWVHIATK-JAXOOIEVSA-N 0.000 claims 1
- JTMGPXOKSXYFLN-FFXKMJQXSA-N Cl.Cl.C1C(C)(C)C=2C=C(F)C(S(=O)(=O)CC)=CC=2N1C(=O)CN1CCN[C@H](C)C1 Chemical compound Cl.Cl.C1C(C)(C)C=2C=C(F)C(S(=O)(=O)CC)=CC=2N1C(=O)CN1CCN[C@H](C)C1 JTMGPXOKSXYFLN-FFXKMJQXSA-N 0.000 claims 1
- ALKVGMVDIMIZFR-FFXKMJQXSA-N Cl.Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C3CC3)=C(F)C=C2C(C)(C)C1 Chemical compound Cl.Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C3CC3)=C(F)C=C2C(C)(C)C1 ALKVGMVDIMIZFR-FFXKMJQXSA-N 0.000 claims 1
- HNVZSBJLIJELHB-GGMCWBHBSA-N Cl.Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C=3C=CC=CC=3)=C(F)C=C2C(C)(C)C1 Chemical compound Cl.Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(S(=O)(=O)C=3C=CC=CC=3)=C(F)C=C2C(C)(C)C1 HNVZSBJLIJELHB-GGMCWBHBSA-N 0.000 claims 1
- NYGGLRWNYQFQKJ-UWGSCQAASA-N Cl.Cl.FC(C)(F)C1=CC2=C(C=N1)C(CN2C(CN2[C@H](CN[C@@H](C2)C)CN2C(CCC2)=O)=O)(C)C Chemical compound Cl.Cl.FC(C)(F)C1=CC2=C(C=N1)C(CN2C(CN2[C@H](CN[C@@H](C2)C)CN2C(CCC2)=O)=O)(C)C NYGGLRWNYQFQKJ-UWGSCQAASA-N 0.000 claims 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 claims 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims 1
- 208000007033 Dysgerminoma Diseases 0.000 claims 1
- 206010062805 Dysplastic naevus Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000006937 Hydatidiform mole Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033963 Parathyroid tumour Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- SXEVBHKSPQCPBR-VEIFNGETSA-N benzyl 6-chloro-1-[2-[(3r)-3-methylpiperazin-1-yl]acetyl]spiro[2h-indole-3,4'-piperidine]-1'-carboxylate;hydrochloride Chemical compound Cl.C1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C2(CCN(CC2)C(=O)OCC=2C=CC=CC=2)C1 SXEVBHKSPQCPBR-VEIFNGETSA-N 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 206010006007 bone sarcoma Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000012191 childhood neoplasm Diseases 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000014616 embryonal neoplasm Diseases 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000003020 exocrine pancreas Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000000284 histiocytoma Diseases 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- PSLUVSXEUAMXRM-GFCCVEGCSA-N methyl 1-[2-[(3r)-3-methylpiperazin-1-yl]acetyl]-2,3-dihydroindole-6-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2CCN1C(=O)CN1CCN[C@H](C)C1 PSLUVSXEUAMXRM-GFCCVEGCSA-N 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000000754 myometrium Anatomy 0.000 claims 1
- BHHKUGBFKGDWBX-CYBMUJFWSA-N n,n-dimethyl-1-[2-[(3r)-3-methylpiperazin-1-yl]acetyl]-2,3-dihydroindole-6-carboxamide Chemical compound C1CN[C@H](C)CN1CC(=O)N1C2=CC(C(=O)N(C)C)=CC=C2CC1 BHHKUGBFKGDWBX-CYBMUJFWSA-N 0.000 claims 1
- LMTJZBHGPKSDRK-GFCCVEGCSA-N n-[1-[2-[(3r)-3-methylpiperazin-1-yl]acetyl]-2,3-dihydroindol-6-yl]methanesulfonamide Chemical class C1CN[C@H](C)CN1CC(=O)N1C2=CC(NS(C)(=O)=O)=CC=C2CC1 LMTJZBHGPKSDRK-GFCCVEGCSA-N 0.000 claims 1
- DYQFFJGPTXIETD-OALZAMAHSA-N n-[[(2r,5r)-1-[2-(6-chloro-3,3-dimethyl-2h-indol-1-yl)-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]acetamide;hydrochloride Chemical compound Cl.CC(=O)NC[C@H]1CN[C@H](C)CN1CC(=O)N1C2=CC(Cl)=CC=C2C(C)(C)C1 DYQFFJGPTXIETD-OALZAMAHSA-N 0.000 claims 1
- JYORITJGHUAKJN-GFCCVEGCSA-N n-methyl-1-[2-[(3r)-3-methylpiperazin-1-yl]acetyl]-2,3-dihydroindole-6-carboxamide Chemical compound C12=CC(C(=O)NC)=CC=C2CCN1C(=O)CN1CCN[C@H](C)C1 JYORITJGHUAKJN-GFCCVEGCSA-N 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 210000002741 palatine tonsil Anatomy 0.000 claims 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 1
- 210000003695 paranasal sinus Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 210000004303 peritoneum Anatomy 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 claims 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims 1
- 125000005289 uranyl group Chemical group 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (17)
1. Spoj formule (I):
[image]
ili tautomerni ili stereokemijski izomerni oblici, N-oksidi, farmaceutski prihvatljive soli ili njihovi solvati; pri čemu
Prsten E predstavlja 6 članu aromatsku karbocikličnu ili heterocikličnu skupinu;
R1 je odabran od C1-4 alkil, C2-4 alkenil i -(CH2)s-C3-8 cikloalkil, pri čemu navedena C1-4 alkil, C2-4 alkenil, i C3-8 cikloalkil može opcionalno biti supstituirana jednom ili više Ra skupina;
Ra je odabran od halogen, -OH i -O-C1-6alkil;
R3a i R3b su neovisno izabrani od hidrogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, -C(=O)NH(2-q)(C1-6 alkil)q, -(CH2)s-(3-12 člani heterociklil), -(CH2)s-C3-12 karbociklil, -C(=O)-(3-12 člani heterociklil), i -C(=O)-C3-12 karbociklil,
ili R3a i R3b skupina, zajedno s atomom ugljika za koji su pričvršćeni, može se pridružiti obliku 3-10 člani zasićeni karbociklil ili heterociklil skupina, pri čemu navedena C1-6 alkil, C2-6 alkenil, C2-6 alkinil, heterociklil i karbociklil skupina može opcionalno biti supstituirana jednom ili više Rb skupina;
R5 je odabran od hidrogen ili C1-6 alkil;
R6 i R7 su neovisno izabrani od hidrogen, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, -I-C3-12 karbociklil, -Z-(3-12 člani heterociklil), -(CRxRy)s-O-Rz, -O-(CRxRy)n- OR z, -(CH2)s-CN, -S(O)q-Rx, -C(=O)Rx, -C(=S)Rx, -C(=N)Rx, -(CRxRy)s-C(=O) ORz, -(CRxRy)sO-C(=O)-Rz, -(CRxRy)s-C(=O)NRxRy, -(CH2)s-NRxC(=O)Ry,-(CH2)s-OC(=O)NRxRy, -(CH2)s-NRxC(=O) ORy, -(CH2)s-NRxRy, -NRx-(CH2)s-Rz,-(CRxRy)s-C(=S)NRz, -(CRxRy)s-C(=N)NRz, -(CH2)s-O-C(=O)-C1-4alkil-NRxRy, -(CH2)s-NRx-(CH2)n-O-C(=O)-Rz, -(CH2)s-NRx-(CH2)s-SO2-Ry, -(CH2)s-NH-SO2-NRxRy i-(CH2)s-SO2NRxRy skupina,
ili R6 i R7 skupina, zajedno s atomom ugljika za koji su pričvršćeni, može se pridružiti obliku 3-10 člani potpuno ili djelomice zasićeni karbociklil ili heterociklil skupina, koja može biti opcionalno spojena s 5-6 članim aromatskim karbociklil ili heterociklil prstenom,
pri čemu navedena C1-8 alkil, C2-8 alkenil i C2-8 alkinil skupina može opcionalno biti supstituirana jednom ili više Rb skupina i pri čemu navedena karbociklil i heterociklil skupina može opcionalno biti supstituirana jednom ili više (npr. 1, 2 ili 3) Rb skupina;
R8 i R9 su neovisno izabrani od hidrogen, halogen, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, -Y-C3-12 karbociklil, -Z-(3-12 člani heterociklil), -(CRxRy)s-O-Rz, - O-(CRxRy)n OR z, =O, =S, nitro, Si(Rx)4, -(CH2)s-CN, -S(O)q-(CRxRy)s-Rz, -C(=O)Rx, - C(=S)Rx, -C(=N)Rx, -(CRxRy)s-C(=O) OR z, -(CRxRy)s-O-C(=O)-Rz, -(CRxRy)s-C(=O)NRxRy, -(CH2)s-NRxC(=O)Ry, -(CH2)s-OC(=O)NRxRy, -(CH2)s-NRxC(=O) OR y, - (CH2)s-NRxRy, -NRx-(CH2)s-Rz, -(CRxRy)s-C(=S)NRz, -(CRxRy)s-C(=N)NRx, - S(O)(=NRx)Ry, -(CH2)s-O-C(=O)-C1-4alkil-NRxRy, -(CH2)s-NRx-(CH2)n-O-C(=O)-Rz, - (CH2)s-NRx-(CH2)s-SO2-Ry, -(CH2)s-NH-SO2-NRxRy, -(CH2)s-SO2NRxRy skupina i - P(=O)(Rx)2, pri čemu navedena C1-8 alkil, C2-8 alkenil i C2-8 alkinil skupina može opcionalno biti supstituirana jednom ili više Rb skupina i pri čemu navedena karbociklil i heterociklil skupina može opcionalno biti supstituirana jednom ili više (npr. 1, 2 ili 3) Rb skupina;
Rb je neovisno odabran od halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, -(CH2)s-C3-8 cikloalkil, -(CH2)s-C3-8 cikloalkenil, -(CH2)s-fenil, -(CH2)s-(4-7 člani zasićeni heterociklil), -(CRxRy)s-O-Rz, -O-(CRxRy)n- OR z, haloC1-6 alkil, haloC1-6 alkoksi, C1-6 alkanol, =O, =S, nitro, Si(Rx)4, -(CH2)s-CN, -S(O)q-Rx, -C(=O)Rx, -(CRxRy)s-C(=O) OR z, -(CRxRy)s-O-C(=O)-Rz, -(CRxRy)s-C(=O)NRxRy, -(CH2)s-NRxC(=O)Ry, - (CH2)s-OC(=O)NRxRy, -(CH2)s-NRxC(=O) OR y, -(CH2)s-NRxRy, -NRx-(CH2)s-Rz, -(CH2)s-O-C(=O)-C1-4alkil-NRxRy, -(CH2)s-NRx-(CH2)n-O-C(=O)-Rz, -(CH2)s-NRx-(CH2)s-SO2-Ry, -(CH2)s-NH-SO2-NRxRy, -(CH2)s-SO2NRxRy skupina i -P(=O)(Rx)2, pri čemu navedena C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-8 cikloalkil, C3-8 cikloalkenil i heterociklil skupina može opcionalno biti supstituirana jednom ili više Rx skupina;
Rx, Ry i Rz neovisno predstavlja halogen, hidrogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, -(CH2)s-C3-8 cikloalkil, -(CH2)s-C3-8 cikloalkenil, -(CH2)s-fenil, -(CH2)s-(4-7 člani zasićeni heterociklil), C1-6 alkanol opcionalno supstituirana jednim ili m ili e halo, -C(=O)OC1-6 alkil, hidroksi, C1-6 alkoksi, haloC1-6 alkil, -(CH2)n-O-C1-6alkil, - C(=O)-(CH2)n-C1-6 alkoksi, -C(=O)-C1-6alkil, -(CH2)s-CN, C1-6 alkil-N(H)2-q(C1-6alkil)q, - N(H)2-q(C1-6alkil)q, -C(=O)-N(H)2-q(C1-6alkil)q, -(CH2)s-NH-SO2-N(H)2-q (C1-6alkil)q, - (CH2)s-N(C1-4alkil)-SO2-N(H)2-q(C1-6alkil)q i -(CH2)s-O-C(=O)-C1-4alkil-N(H)2-q(C1-6alkil)q, i kada je povezan s atomima dušika, ugljika, silicija ili fosfora Rx i Ry mogu se pridružiti obliku 3-7 člani prsten opcionalno sadrži jedan ili dva dodatna heteroatoma odabrana od O, N, S i oksidiran oblik od N ili S;
Y i Z su neovisno izabrani od veze , -(CRxRy)m-, -C(=CRx)-, -C(=O)-, - NRx-, -C(=O)NRx-, -NRxC(=O)-, -(CRxRy)q-O-, -O-(CRxRy)q-, -S(O)2-NH-, -NH-S(O)2- i -S(O)q-;
s neovisno predstavlja n integral od 0-4;
n neovisno predstavlja n integral od 1-4;
p neovisno predstavlja n integral od 0-4;
q predstavlja n integral od 0-2; i
m predstavlja n integral od 1-2.
2. Spoj sukladno zahtjevu 1, pri čemu prsten E predstavlja piridil, piridazinil ili fenil.
3. Spoj sukladno zahtjevu 2, pri čemu prsten E predstavlja piridil.
4. Spoj sukladno bilo kojem od zahtjeva 1 do 3, pri čemu R1 predstavlja metil.
5. Spoj sukladno bilo kojem od zahtjeva 1 do 4, pri čemu:
(i) R3a i R3b su neovisno izabrani od hidrogen, C1-6 alkil, -C(=O)NH(2-q)(C1-6 alkil)q, -(CH2)s-(3-12 člani heterociklil), -(CH2)s-C3-12 karbociklil, -C(=O)-(3-12 člani heterociklil), i -C(=O)-C3-12 karbociklil pri čemu navedena C1-6 alkil, heterociklil i karbociklil skupina može opcionalno biti supstituirana jednom ili više Rb skupina; ili
(ii) R3b je hidrogen, i R3a je
-CH2-(6 člani zasićeni heterociklil), poput -CH2-piperidinil, -CH2-piperazinil ili -CH2-morfolinil, pri čemu navedena heterociklil skupina može opcionalno biti supstituirana jednom ili više Rb skupina (npr. =O, C1-6 alkil (poput metil ili etil) ili -(CRxRy)s-O-Rz (npr. -CH2OCH3)); ili
(iii) R3bje hidrogen, i R3a je -CH2-(4-morfolinil) opcionalno supstituirana a jednom ili više Rb skupina (npr. C1-6 alkil, poput metil).
6. Spoj sukladno bilo kojem od zahtjeva 1 do 5, pri čemu R5 predstavlja hidrogen.
7. Spoj sukladno bilo kojem od zahtjeva 1 do 6, pri čemu:
(i) R6 i R7 su neovisno izabrani od hidrogen, C1-6 alkil, -Y-C3-12 karbociklil, -Z-(3-12 člani heterociklil), -(CRxRy)s-C(=O) OR z ili -(CRXRy)s-O-Rz; ili
(ii) R6 i R7 su oba metil; ili
(iii) R6 i R7 skupina, zajedno s atomom ugljika za koji su pričvršćeni, spajaju se da bi formirali 3-6 člani potpuno zasićeni karbociklil ili heterociklil skupina, i koja može biti opcionalno spojena 5-6 člani aromatski karbociklil ili heterociklil prsten , pri čemu navedena karbociklil i heterociklil skupina može opcionalno biti supstituirana a od 1, 2 ili 3 Rb skupina.
8. Spoj sukladno bilo kojem od zahtjeva 1 to 7, pri čemu p je 0, ili p je 1 i R8 je odabran od halogen, =O, C1-6 alkil i -(CRxRy)s-O-Rz.
9. Spoj sukladno bilo kojem od zahtjeva 1 to 8, pri čemu:
(i) R9 je odabran od halogen, -(CH2)s-CN, C1-8 alkil, -Y-C3-12 karbociklil, -Z-(3-12 člani heterociklil), -S(O)q-(CRxRy)s-Rz ili -(CH2)s-SO2NRxRy, pri čemu navedena karbociklil skupina ili heterociklil skupina može opcionalno biti supstituirana jednom ili više Rb skupina poput =O, halogen, C1-6 alkil, -(CH2)s-CN ili -(CRxRy)s-O-Rz; ili
(ii) R9 je odabran od klora, floura, broma,-CN, metil, etil, propil, izobutil, butil, -(CH2)2-CH(CH3)2, -CH2-fenil, -CF2-fenil, -CH(CH3)-fenil, -CH(OCH3)-fenil, -C(=CH2)-fenil, -O-fenil, -SO2-fenil, -C(=O)-fenil, -CF2-ciklopropil, - CF2-ciklobutil, -CF2-CH2-ciklobutil, -ciklopentil, -ciklopentenil, -CH2-cikloheksil, cikloheksil, cikloheksenil, -pirazoil, -furanil, -thienil, -oksadiazolil, -tetrazolil, - benzod uranil, -CH2-pirrolidinil,-SO2CH3, -SO2-CH2CH(CH3)2, -SO2-CH2-fenil, - SO2N(CH3)2, pri čemu navedena fenil, pirazoil, furanil, thienil, oksadiazolil, tetrazolil, benzod uranil ili pirrolidinil skupina može opcionalno biti supstituirana jednom ili više Rb skupina poput =O, fluorina, klorina, metil,-CN ili metoksi; ili
(iii) R9 je odabran od -(CRxRy)1-2-ciklopropil, -(CRxRy)-ciklobutil,-(CRxRy)-fenil, etil, propil ili butil svaki od kojih može opcionalno biti supstituirana jednim ili više atoma halogena (npr. fluorina) i pri čemu Rx i Ry su neovisno izabrani od hidrogen i fluorina; ili
(iv) R9 is -CH2-(4-fluorofenil).
10. Spoj sukladno zahtjevu 1, koji je spoj formule (Ii)a ili (Ii)b:
[image]
ili tautomerni ili stereokemijski izomerni oblici, N-oksidi , farmaceutski prihvatljive soli ili njihovi solvati; pri čemu R3a, R6, R7 i R9 su sukladno definicijama u zahtjevima 1 do 9.
11. Spoj sukladno zahtjevu 1, koji je spoj formule (Ic):
[image]
ili tautomerni ili stereokemijski izomerni oblici, N-oksidi, farmaceutski prihvatljive soli ili njihovi solvati, pri čemu:
A je N, U je CR8 i V je CR9;
i pri čemu R1, R3a, R6, R7, R8 i R9 su kako je definirano u bilo kojem od zahtjeva 1 do 9.
12. Spoj sukladno zahtjevu 1, pri čemu je spoj slobodna baza spoja odabranog od:
1-(6-Bromo-2,3-dihidro-indol-1 -il)-2-((R)-3-metil-piperazin-1 -il)-etanon;
1-[6-(Metil-fenil-amino)-2,3-dihidro-indol-1-il]-2-((R)-3-metil-piperazin-1-il)-etanon Trifluoracetat sol;
2-((R)-3-Metil-piperazin-1-il)-1-(6-fenilamino-2,3-dihidro-indol-1-il)-etanon Trifluoracetat sol;
1-(6-Kloro-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-(6-Metoksi-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-(6-Metil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-(6-Amino-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
N-{1-[2-((R)-3-Metil-piperazin-1-il)-acetil]-2,3-dihidro-1H-indol-6-il}-metanesulfonamide;
1-(5-Fluoro-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-(6-Fluoro-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-(5-Bromo-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-(6-Bromo-2,3-dihidro-indol-1-il)-2-((2S,5R)-2-isopropil-5-metil-piperazin-1-il)-etanon;
1-(6-Isopropil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-(2,3-Dihidro-pirolo[3,2-c]piridin-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-[2-((R)-3-Metil-piperazin-1-il)-acetil]-2,3-dihidro-1H-indol-6-karboksilna kiselina metil ester;
1-[2-((R)-3-Metil-piperazin-1-il)-acetil]-2,3-dihidro-1H-indol-6-karboksilna kiselina metilamide;
1-[2-((R)-3-Metil-piperazin-1-il)-acetil]-2,3-dihidro-1H-indol-6-karboksilna kiselina dimetilamid ;
2-((R)-3-Metil-piperazin-1-il)-1-[6-(pirrolidin-1-karbonil)-2,3-dihidro-indol-1-il]-etanon;
1-(4-Kloro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-(6-Kloro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-(3,3-Dimetil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
2-((R)-3-Metil-piperazin-1-il)-1-(6-trifluorometil-2,3-dihidro-indol-1-il)-etanon;
Benzil 6-kloro-1-{2-[(3R)-3-metilpiperazin-1-il]acetil}-1,2-dihidrospiro[indol-3,4'-piperidin]-1'-karboksilat hidroklorid sol;
1-(5-Fluoro-6-fenil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon hidroklorid sol;
5-Bromo-1-[2-((R)-3-metil-piperazin-1-il)-acetil]-2,3-dihidro-1H-indol-6-sulfinska kiselina metilamid hidroklorid sol;
5-Bromo-1-[2-((R)-3-metil-piperazin-1-il)-acetil]-2,3-dihidro-1H-indol-6- sulfinska kiselina dimetilamid hidroklorid sol;
1-[2-((R)-3-Metil-piperazin-1-il)-acetil]-2,3-dihidro-1H-indol-6- sulfinska kiselina metilamide;
2-((R)-3-Metil-piperazin-1-il)-1-(6-trifluorometoksi-2,3-dihidro-indol-1-il)-etanon hidroklorid sol;
1-(6-Benzil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon hidroklorid sol;
1-(6-Metanesulfonil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon hidroklorid sol;
1-{1'-Acetil-6-kloro-1,2-dihidrospiro[indol-3,4'-piperidine]-1-il}-2-[(3R)-3-metilpiperazin-1-il]etan-1-on hidroklorid sol;
1-[2-((R)-3-Metil-piperazin-1-il)-acetil]-2,3-dihidro-1H-indol-6- sulfinska kiselina dimetilamid ;
1-(6-Benzensulfonil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon hidroklorid sol;
1-(6-Kloro-2,3-dihidro-pirolo[3,2-c]piridin-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon hidroklorid sol;
1-(6-Benzil-2,3-dihidro-pirolo[3,2-c]piridin-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon hidroklorid sol;
1-(2,3-Dihidro-pirolo[2,3-b]piridin-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon dihidroklorid sol;
2-((R)-3-Metil-piperazin-1-il)-1-[6-(pirrolidin-1-sulfonil)-2,3-dihidro-indol-1-il]-etanon hidroklorid sol;
1-[6-(5-Kloro-2-fluoro-fenil)-2,3-dihidro-pirolo[3,2-c]piridin-1-il]-2-((R)-3-metil-piperazin-1-il)-etanon hidroklorid sol;
6-Benzil-1-[2-((R)-3-metil-piperazin-1-il)-acetil]-1,2,3,6-tetrahidro-pirolo[2,3-c]piridin-5-on hidroklorid sol;
1-(6-Kloro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((2R,5R)-2-hidroksimetil-5-metil-piperazin-1-il)-etanon hidroklorid sol;
1-(6-Benzensulfonil-5-fluoro-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon;
1-(6-Benzil-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((2R,5R)-2-hidroksimetil-5-metil-piperazin-1-il)-etanon trifluoracetat sol;
1-(6-Benzensulfonil-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon hidroklorid sol;
1-(6-Kloro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid sol;
N-{(2R,5R)-1-[2-(6-Kloro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-oxo-etil]-5-metil-piperazin-2-ilmetil}-acetamid hidroklorid sol;
1-(4,6-Dikloro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon hidroklorid sol;
1-(6-Benzensulfonil-5-fluoro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon dihidroklorid sol;
1-(6-Benzensulfonil-5-fluoro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((2S,5R)-2-etil-5-metil-piperazin-1-il)-etanon dihidroklorid sol;
1-[5-Fluoro-3,3-dimetil-6-(pirrolidin-1-sulfonil)-2,3-dihidro-indol-1-il]-2-((R)-3-metil-piperazin-1-il)-etanon dihidroklorid sol;
1-{6'-Kloro-1',2'-dihidrospiro[ciklopentan-1,3'-indol]-1'-il}-2-[(3R)-3-metilpiperazin-1-il]etan-1-on hidroklorid sol;
1-(6-Etanesulfonil-5-fluoro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon dihidroklorid sol;
1-[5-Fluoro-3,3-dimetil-6-(propane-2-sulfonil)-2,3-dihidro-indol-1-il]-2-((R)-3-metil-piperazin-1-il)-etanon dihidroklorid sol;
1-{6'-Kloro-1',2'-dihidrospiro[ciklopropan-1,3'-indol]-1'-il}-2-[(3R)-3-metilpiperazin-1-il]etan-1-on hidroklorid sol;
(2R,5R)-1-[2-(6-Kloro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-oxo-etil]-5-metilpiperazin-2-karboksilna kiselina metilamid hidroklorid sol;
1 -{6'-Kloro-1',2'-dihidrospiro[ciklobutane-1,3'-indol]-1'-il}-2-[(3R)-3-metilpiperazin-1-il]etan-1-on hidroklorid sol;
(2R,5R)-1-[2-(6-Benzensulfonil-5-fluoro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-oksoetil]-5-metil-piperazin-2-karboksilna kiselina metilamid hidroklorid sol;
1-(6-Ciklopropansulfonil-5-fluoro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((R)-3-metil-piperazin-1-il)-etanon dihidroklorid sol;
1-(6-Benzensulfonil-5-fluoro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid sol;
1-(6-Etansulfonil-3,3-dimetil-2,3-dihidro-indol-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon dihidroklorid sol;
1-[5-Fluoro-6-(4-metoksi-benzensulfonil)-3,3-dimetil-2,3-dihidro-indol-1-il]-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon dihidroklorid sol;
1-[2-((2R,5R)-2-Metoksimetil-5-metil-piperazin-1-il)-acetil]-3,3-dimetil-2,3-dihidro-1H-indol-6- sulfinska kiselina metilamid dihidroklorid sol;
1-(6-Kloro-3,3-dimetil-2,3-dihidro-pirolo[3,2-c]piridin-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid sol;
1-(6-Benzil-3,3-dimetil-2,3-dihidro-pirolo[3,2-c]piridin-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid sol;
1-[3,3-Dimetil-6-(2-metil-propane-1-sulfonil)-2,3-dihidro-indol-1-il]-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon dihidroklorid sol;
1-(5-Metoksi-3,3-dimetil-2,3-dihidro-pirolo[2,3-c]piridin-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid sol;
1-[2-((2R,5R)-2-Metoksimetil-5-metil-piperazin-1-il)-acetil]-3,3,6-trimetil-1,2,3,6-tetrahidro-pirolo[2,3-c]piridin-5-on hidroklorid sol;
6-Benzil-1-[2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-acetil]-3,3-dimetil-1,2,3,6-tetrahidro-pirolo[2,3-c]piridin-5-on hidroklorid sol;
1-[2-((2R,5R)-2-Metoksimetil-5-metil-piperazin-1-il)-acetil]-3,3-dimetil-2,3-dihidro-1H-indol-6- sulfinska kiselina dimetilamid dihidroklorid sol;
1-[2-((2R,5R)-2-Metoksimetil-5-metil-piperazin-1-il)-acetil]-3,3-dimetil-2,3-dihidro-1H-indol-6- sulfinska kiselina isopropilamid dihidroklorid sol;
1-(3,3-Dimetil-6-fenilmetanesulfonil-2,3-dihidro-indol-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon dihidroklorid sol;
1-{1-Acetil-6'-kloro-1',2'-dihidrospiro[azetidine-3,3'-indol]-1'-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid sol;
1-(6-Izobutil-3,3-dimetil-2,3-dihidro-pirolo[3,2-c]piridin-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon;
6-Izobutil-1-[2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-acetil]-3,3-dimetil-1,2,3,6-tetrahidro-pirolo[2,3-c]piridin-5-on hidroklorid sol;
1-(3,3-Dimetil-6-fenoksi-2,3-dihidro-pirolo[3,2-c]piridin-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid sol;
1-[3,3-Dimetil-6-(3-metil-butil)-2,3-dihidro-pirolo[3,2-c]piridin-1-il]-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon;
1-{1-Acetil-6'-benzil-1',2'-dihidrospiro[azetidine-3,3'-indol]-1'-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid sol;
1-{6-[(2-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on;
1-{6-[(2-Klorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid sol;
1-[6-(Cikloheksilmetil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on;
3-[(1-{2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]aceti1}-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-6-il)metil]benzonitril hidroklorid sol;
1-(3,3-Dimetil-6-fenilamino-2,3-dihidro-pirolo[3,2-c]piridin-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid sol;
1-[6-(4-Kloro-benzil)-3,3-dimetil-2,3-dihidro-pirolo[3,2-c]piridin-1-il]-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon;
1-(3,3-Dimetil-6-o-toliloksi-2,3-dihidro-pirolo[3,2-c]piridin-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid sol;
1-[3,3-Dimetil-6-(metil-fenil-amino)-2,3-dihidro-pirolo[3,2-c]piridin-1-il]-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid sol;
1-(2,3-Dihidro-1H-indol-1-il)-2-[(3R)-3-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-{6-[(3-Klorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-[3,3-Dimetil-6-(1-feniletil)-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-{6-[(4-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]-1-{6-[(3-metoksifenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}etan-1-on, hidroklorid sol;
1-[6-(Ciklopent-1-en-1-il)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2S,5R)-2-etil-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-{6-Ciklopentil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-[3,3-Dimetil-6-(1-fenilethenil)-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-(6-Benzil-3,3-dimetil-2,3-dihidro-1H-indol-1-il)-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-[3,3-Dimetil-6-(1H-pirazol-1-ilmetil)-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2S,5R)-2-etil-5-metilpiperazin-1-il]etan-1-on;
1-{6-Benzoil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, dihidroklorid sol;
1-{6-[(3-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]-1-{6-[(4-metoksifenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}etan-1-on, hidroklorid sol;
(2R,5R)-1-(2-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-N,N,5-trimetilpiperazin-2-karboksamid, hidroklorid sol;
2-[(2R,5R)-2-[(Azetidin-1-il)karbonil]-5-metilpiperazin-1-il]-1-{6-benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}etan-1-on, hidroklorid sol;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-[(morfolin-4-il)karbonil]piperazin-1-il]etan-1-on, hidroklorid sol;
1-(1-{2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]acetil}-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-6-il)pirrolidin-2-on, hidroklorid sol;
1-{2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]acetil}-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-6-karbonitril;
(2R,5R)-1-(2-{6-Benzil-3-[(benziloksi)metil]-3-metil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-N,N,5-trimetilpiperazin-2-karboksamid, hidroklorid sol;
1-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-[6-(Cikloheks-1-en-1-il)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-(3-Benzil-6-kloro-3-metil-2,3-dihidro-1H-indol-1-il)-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on, hidroklorid sol;
1-(6-Kloro-3,3-dimetil-2,3-dihidro-indol-1-il)-2-[(2R,5R)-5-metil-2-(morfoline-4-karbonil)-piperazin-1-il]-etanon, hidroklorid sol;
1'-{2-[(2R,5R)-5-Metil-2-[(morfolin-4-il) karbonil]piperazin-1-il]acetil}-1,1',2',3-tetrahidrospiro[inden-2,3'-indol]-6'-karbonitril, hidroklorid sol;
1-[6-(2-Kloro-fenoksi)-3,3-dimetil-2,3-dihidro-pirolo[3,2-c]piridin-1-il]-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon, hidroklorid sol;
1-(6-Benzil-3,3-dimetil-2,3-dihidro-indol-1-il)-2-[(2R,5R)-5-metil-2-(morfoline-4-karbonil)-piperazin-1-il]-etanon, hidroklorid sol;
1-(6-Benzil-3,3-dimetil-2,3-dihidro-pirolo[3,2-c]piridin-1-il)-2-((2R,5R)-5-metil-2-pirazol-1-ilmetil-piperazin-1-il)-etanon;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[3-(trifluorometil)piperazin-1-il]etan-1-on;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[3-(fluorometil)piperazin-1-il]etan-1-on;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(3S)-3-(fluorometil)piperazin-1-il]etan-1-on;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(3R)-3-(fluorometil)piperazin-1-il]etan-1-on;
1-{2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]acetil}-3,3-dimetil-2,3-dihidro-1H-indol-6-karbonitrilhidroklorid;
1-{6-Cikloheksil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-[6-(2,6-Dimetilfenoksi)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{6'-Kloro-1,1',2',3-tetrahidrospiro[inden-2,3'-indol]-1'-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(fluorometil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(difluorometil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-(6-Kloro-3-etil-3-metil-2,3-dihidro-1H-indol-1-il)-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-[3,3-Dimetil-6-(1-metil-1H-pirazol-4-il)-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-[(1-{2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]acetil}-3,3-dimetil-2,3-dihidro-1H-indol-6-il)metil]pirrolidin-2-onhidroklorid;
1-[3,3-Dimetil-6-(thiofen-3-il)-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-[6-Bromo-3-(metoksimetil)-3-metil-2,3-dihidro-1H-indol-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-[6-(2,6-Difluorofenoksi)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
Metil 6-bromo-1-{2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]acetil}-3-metil-2,3-dihidro-1H-indol-3-karboksilathidroklorid;
1-[6-(2-Kloro-6-metilfenoksi)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{6-Benzil-3,3-dimetil-1 H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-[(pirrolidin-1-il)karbonil]piperazin-1-il]etan-1-on dihidroklorid;
1-{6-[Metoksi(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-[(piperidin-1-il)karbonil]piperazin-1-il]etan-1-on dihidroklorid;
1-{2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]acetil}-3,3,5-trimetil-2,3-dihidro-1H-indol-6-karbonitril;
1-(6-Kloro-3,3-dietil-2,3-dihidro-1H-indol-1-il)-2-[(2R,5R)-5-metil-2-[(morfolin-4-il)karbonil]piperazin-1-il]etan-1-on hidroklorid;
1-{2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]acetil}-3-metil-3-fenil-2,3-dihidro-1H-indol-6-karbonitril;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-(6-Kloro-3,3-dimetil-2,3-dihidro-1H-indol-1-il)-2-[(2R,5R)-5-metil-2-(1H-pirazol-1-ilmetil)piperazin-1-il]etan-1-on hidroklorid;
(3S)-1-{2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]acetil}-3-metil-3-fenil-2,3-dihidro-1H-indol-6-karbonitril;
(3R)-1-{2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]acetil}-3-metil-3-fenil-2,3-dihidro-1H-indol-6-karbonitril;
1-[6-Kloro-3,3-dimetil-5-(3-metil-1,2,4-oksadiazol-5-il)-2,3-dihidro-1H-indol-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on;
1-{6'-Kloro-1,1',2',3-tetrahidrospiro[inden-2,3'-indol]-1'-il}-2-[(2R,5R)-5-metil-2-(1H-pirazol-1-ilmetil)piperazin-1-il]etan-1-onhidroklorid;
3-Metil-1-{2-[(2R,5R)-5-metil-2-(1H-pirazol-1-ilmetil)piperazin-1-il]acetil}-3-fenil-2,3-dihidro-1H-indol-6-karbonitril hidroklorid;
1-[6-Benzil-3-metil-3-(piridin-2-il)-2,3-dihidro-1H-indol-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-[6-(Furan-3-il)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-[(4-metil-1H-pirazol-1-il)metil]piperazin-1-il]etan-1-onhidroklorid;
1-[3,3-Dimetil-6-(5-metilthiofen-2-il)-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
3-Metil-1-{2-[(2R,5R)-5-metil-2-[(morfolin-4-il)karbonil]piperazin-1-il]acetil}-3-fenil-2,3-dihidro-1H-indol-6-karbonitril hidroklorid;
1-[6-(1-Benzod uran-2-il)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
(2R,5R)-1-{2-[6-(2-Klorofenoksi)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-oksoetil}-N,N,5-trimetilpiperazin-2-karboksamid dihidroklorid;
(3S)-3-Metil-1-{2-[(2R,5R)-5-metil-2-[(morfolin-4-il)karbonil]piperazin-1-il]acetil}-3-fenil-2,3-dihidro-1H-indol-6-karbonitril;
(3R)-3-Metil-1-{2-[(2R,5R)-5-metil-2-[(morfolin-4-il)karbonil]piperazin-1-il]acetil}-3-fenil-2,3-dihidro-1H-indol-6-karbonitril;
(3S)-3-Metil-1-{2-[(2R,5R)-5-metil-2-(1H-pirazol-1-ilmetil)piperazin-1-il]acetil}-3-fenil-2,3-dihidro-1H-indol-6-karbonitril;
(3R)-3-Metil-1-{2-[(2R,5R)-5-metil-2-(1H-pirazol-1-ilmetil)piperazin-1-il]acetil}-3-fenil-2,3-dihidro-1H-indol-6-karbonitril;
1-{2-[(2R,5R)-2-(Metoksimetil)-5-metilpiperazin-1-il]acetil}-3-metil-3-(piridin-2-il)-2,3-dihidro-1H-indol-6-karbonitril hidroklorid;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-[(4-fluoro-1H-pirazol-1-il)metil]-5-metilpiperazin-1-il]etan-1-on hidroklorid;
(2R,5R)-1-(2-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-N,N,5-trimetilpiperazin-2-karboksamid dihidroklorid;
1-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-[(4-metil-1H-pirazol-1-il)metil]piperazin-1-il]etan-1-on dihidroklorid;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-5-metil-2-[(morfolin-4-il)karbonil]piperazin-1-il]etan-1-on dihidroklorid;
1'-{2-[(2R,5R)-5-Metil-2-[(4-metil-1H-pirazol-1-il)metil]piperazin-1-il]acetil}-1, 1',2',3-tetrahidrospiro[inden-2,3'-indol]-6'-karbonitril;
3,3-Dimetil-1-{2-[(3R)-3-metilpiperazin-1-il]acetil}-2,3-dihidro-1H-indol-6-karbonitril;
1-[6-Benzil-3-metil-3-(piridin-3-il)-2,3-dihidro-1H-indol-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-N,N,5-trimetilpiperazin-2-karboksamid dihidroklorid;
1-[6-(2-Klorofenoksi)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-5-metil-2-[(morfolin-4-il)karbonil]piperazin-1-il]etan-1-on dihidroklorid;
6-[(2,4-Difluorofenil)metil]-1-{2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]acetil}-3,3-dimetil-1H,2H,3H-1,5λ5-pirolo[3,2-c][1λ5]piridin-5-on hidroklorid;
(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-5-oxo-1H,2H,3H-1,5A5-pirolo[3,2-c][1λ5]piridin-1-il}-2-oksoetil)-N,N,5-trimetilpiperazin-2-karboksamid hidroklorid;
1-[(3R)-6-Bromo-3-(metoksimetil)-3-metil-2,3-dihidro-1H-indol-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-[(3S)-6-Bromo-3-(metoksimetil)-3-metil-2,3-dihidro-1H-indol-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
(2R,5R)-1-(2-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-oksoetil)-N,N,5-trimetilpiperazin-2-karboksamid dihidroklorid;
1-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-2-[(4-fluoro-1H-pirazol-1-il)metil]-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{[(2R,5R)-1-(2-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on dihidroklorid;
1-{[(2R,5R)-1-(2-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on dihidroklorid;
1-[(3R)-6-Benzil-3-metil-3-(3-metil-1,2-oksazol-5-il)-2,3-dihidro-1H-indol-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-[(3S)-6-Benzil-3-metil-3-(3-metil-1,2-oksazol-5-il)-2,3-dihidro-1H-indol-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-[(4-fluoro-1H-pirazol-1-il)metil]-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-[6-(2-Klorofenoksi)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-[(4-fluoro-1H-pirazol-1-il)metil]-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-[(morfolin-4-il)karbonil]piperazin-1-il]etan-1-on dihidroklorid;
1-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
1-{[(2R,5R)-1-(2-{6-Benzil-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on dihidroklorid;
1-[6-(1,1-Difluoroetil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{[(2R,5R)-1-{2-[6-(2-Klorofenoksi)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
1-{3-Kloro-7,7-dimetil-5H,6H,7H-pirolo[3,2-c]piridazin-5-il}-2-[(2R,5R)-2-(metoksimetil)-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{[(2R,5R)-1-{2-[6-(1,1-Difluoroetil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on dihidroklorid;
1-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}-1,2-dihidropirimidin-2-on dihidroklorid;
1-[6-(1,1-Difluoropropil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-{[(3R)-3-metilmorfolin-4-il]metil}piperazin-1-il]etan-1-on hidroklorid;
1-{[(2R,5R)-1-(2-{6-Benzoil-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on dihidroklorid;
1-{[(2R,5R)-1-{2-[6-(1,1-Difluoroetil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on dihidroklorid;
3-{[(2R,5R)-1-{2-[6-(2-Klorofenoksi)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}-1,3-oksazolidin-2-on hidroklorid;
1-{[(2R,5R)-1-{2-[6-(1,1-Difluoropropil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
4-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}morfolin-3-on hidroklorid;
1-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}piperidin-2-on hidroklorid;
1-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}-1,2-dihidropiridin-2-on dihidroklorid;
2-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}-2,3-dihidropiridazin-3-on dihidroklorid;
1-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}-1,2-dihidropirazin-2-on dihidroklorid;
3,3-Dimetil-1-[(2S)-2-[(3R)-3-metilpiperazin-1-il]propanoil]-2,3-dihidro-1H-indol-6-karbonitril hidroklorid;
1-{[(2R,5R)-1-(2-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}-3-metilimidazolidin-2-on hidroklorid;
1-{[(2R,5R)-1-{2-[6-(1,1-Difluoropropil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on;
1-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on dihidroklorid;
3-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}-1,3-oksazolidin-2-on dihidroklorid;
1-{[(2R,5R)-1-(2-{3-[(2,4-Difluorofenil)metil]-7,7-dimetil-5H,6H,7H-pirolo[3,2-c]piridazin-5-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
1-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-{[(3S)-3-fluoropirrolidin-1-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-{[(3R)-3-fluoropirrolidin-1-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-2-{[(3S)-3-fluoropirrolidin-1-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-2-{[(3R)-3-fluoropirrolidin-1-il]metil}-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-[(dimetil-1H-1,2,4-triazol-1-il)metil]-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-3-on dihidroklorid;
1-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-[(3,3-difluoropirrolidin-1-il)metil]-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
3-{[(2R,5R)-1-(2-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}-1,3-oksazolidin-2-on dihidroklorid;
1-{[(2R,5R)-1-(2-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
1-{[(2R,5R)-1-{2-[6-(1,1-Difluoro-2-metilpropil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
1-{[(2R,5R)-1-{2-[6-(Ciklopropildifluorometil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
1-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-2-{[(3R)-3-f!u ili opirro!idin-1-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-[6-(1,1-Difluoropropil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-2-{[(3R)-3-fluoropirrolidin-1-il]metil}-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{[(2R,5R)-1-(2-{6-[(4-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on dihidroklorid;
1-{[(2R,5R)-1-{2-[6-(1,1-Difluoro-3-metilbutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on dihidroklorid;
1-{[(2R,5R)-1-{2-[6-(1,1-Difluorobutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
1-{[(2R,5R)-1-(2-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2,5-dion dihidroklorid;
1-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on dihidroklorid;
1-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-(pirrolidin-1-ilmetil)piperazin-1-il]etan-1-on dihidroklorid;
1-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-2-{[(3R)-3-fluoropirrolidin-1-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-[6-(1,1-Difluoroetil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-{1H,2H,3H-pirolo[2,3-b]piridin-1-ilmetil}piperazin-1-il]etan-1-on dihidroklorid;
1-[6-(1,1-Difluorobutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-2-{[(3R)-3-fluoropirrolidin-1-il]metil}-5-metilpiperazin-1-il]etan-1-on hidroklorid;
1-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on dihidroklorid;
1-{[(2R,5R)-1-{2-[6-(1,1-Difluoro-3-metilbutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
1-{[(2R,5R)-1-{2-[6-(Ciklobutildifluorometil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolid in-2-on dihidroklorid;
1-{[(2R,5R)-1-{2-[6-(1,1-Difluorobutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
4-{[(2R,5R)-1-{2-[6-(1,1-Difluoroetil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}-1-metilpiperazin-2-on dihidroklorid;
1-[6-(1,1-Difluoro-3-metilbutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on hidroklorid;
1-{[(2R,5R)-1-{2-[6-(2-Ciklopropil-1,1-difluoroetil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-oksoetil}-5-metilpiperazin-2-il]metil}pirrolidin-2-on f ili mate;
1-[6-(2-Ciklopropil-1,1-difluoroetil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on dihidroklorid;
1-{6-[Difluoro(fenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on dihidroklorid;
1-[6-(1,1-Difluorobutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2S,5R)-5-metil-2-(1,3-thiazol-2-ilmetil)piperazin-1-il]etan-1-on hidroklorid;
1-{6-[(4-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on dihidroklorid;
1-[6-(1,1-Difluoro-3-metilbutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on;
1-{6-[(2,4-Difluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on dihidroklorid;
1-{6-[(4-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on hidroklorid;
1-[6-(1,1-Difluorobutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on hidroklorid;
1-[6-(1,1-Difluorobutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on hidroklorid;
1-{6-[(4-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-5-metil-2-{[(3S)-3-metilmorfolin-4-il]metil}piperazin-1-il]etan-1-on dihidroklorid;
1-{6-[(4-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-2-{[(3R)-3-fluoropirrolidin-1-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{[(2R,5R)-1-(2-{6-[(2-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
2-[(2R,5R)-2-{[(2R,68)-2,6-Dimetilmorfolin-4-il]metil}-5-metilpiperazin-1-il]-1-{6-[(4-fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}etan-1-on dihidroklorid;
1-{6-[(2-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-{[(3R)-3-metilmorfolin-4-il]metil}piperazin-1-il]etan-1-on hidroklorid;
1-{6-[(2-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on hidroklorid;
1-[6-(1,1-Difluorobutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-2-{[(2R,68)-2,6-dimetilmorfolin-4-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{6-[(2-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-5-metil-2-(morfolin-4-ilmetil)piperazin-1-il]etan-1-on dihidroklorid;
1-[6-(1,1-Difluorobutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-2-{[(3R)-3-etilmorfolin-4-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{[(2R,5R)-1-(2-{6-[(2-Fluorofenil)metil]-3,3-dimetil-1 H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-oksoetil)-5-metilpiperazin-2-il]metil}pirrolidin-2-on hidroklorid;
1-{6-[(2-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}-2-[(2R,5R)-2-{[(3R)-3-fluoropirrolidin-1-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-{6-[(4-Fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il}-2-[(2R,5R)-5-metil-2-{[(3R)-3-metilmorfolin-4-il]metil}piperazin-1-il]etan-1-on dihidroklorid;
1-[6-(1,1-Difluorobutil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-c]piridin-1-il]-2-[(2R,5R)-5-metil-2-{[(3R)-3-metilmorfolin-4-il]metil}piperazin-1-il]etan-1-on dihidroklorid;
1-[6-(1,1-Difluoroetil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-2-{[(3R)-3-etilmorfolin-4-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
2-[(2R,5R)-2-{[(3R)-3-Etilmorfolin-4-il]metil}-5-metilpiperazin-1-il]-1-{6-[(4-fluorofenil)metil]-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il}etan-1-on dihidroklorid;
1-[6-(1,1-Difluoropropil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-2-{[(3R)-3-etilmorfolin-4-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-[6-(1,1-Difluoropropil)-3,3-dimetil-1H,2H,3H-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-2-{[(3R)-3-(metoksimetil)morfolin-4-il]metil}-5-metilpiperazin-1-il]etan-1-on dihidroklorid;
1-(6-Benzil-3,3-dimetil-2,3-dihidro-pirolo[2,3-b]piridin-1-il)-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid;
1-[3,3-Dimetil-6-(1H-tetrazol-5-il)-2,3-dihidro-indol-1-il]-2-((2R,5R)-2-metoksimetil-5-metil-piperazin-1-il)-etanon hidroklorid;
1-[6-(4-Fluoro-benzil)-3,3-dimetil-2,3-dihidro-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-((R)-3-metil-morfolin-4-ilmetil)-piperazin-1-il]-etanon dihidroklorid;
1-[6-(1,1-Difluoro-butil)-3,3-dimetil-2,3-dihidro-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-((R)-3-metil-morfolin-4-ilmetil)-piperazin-1-il]-etanon dihidroklorid;
1-[6-(2-Fluoro-benzil)-3,3-dimetil-2,3-dihidro-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-((R)-3-metil-morfolin-4-ilmetil)-piperazin-1-il]-etanon dihidroklorid;
1-[6-(4-Fluoro-benzil)-3,3-dimetil-2,3-dihidro-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-((R)-3-metil-morfolin-4-ilmetil)-piperazin-1-il]-etanon;
1-[6-(4-Fluoro-benzil)-3,3-dimetil-2,3-dihidro-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-((R)-3-metil-morfolin-4-ilmetil)-piperazin-1-il]-etanon;
1-[6-(4-Fluoro-benzil)-3,3-dimetil-2,3-dihidro-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-((R)-3-metil-morfolin-4-ilmetil)-piperazin-1-il]-etanon hidroklorid;
1-[6-(2,4-Difluoro-benzil)-3,3-dimetil-2,3-dihidro-pirolo[3,2-b]piridin-1-il]-2-[(2R,5R)-5-metil-2-((R)-3-metil-morfolin-4-ilmetil)-piperazin-1-il]-etanon, dihidroklorid;
1-[6-(4-Fluoro-benzil)-3,3-dimetil-2,3-dihidro-pirolo[3,2-b]piridin-1-il]-2-((R)-3-metil-piperazin-1-il)-etanon; i
3,3-Dimetil-1-[(2S)-2-[(3R)-3-metilpiperazin-1-il]butanoil]-2,3-dihidro-1H-indol-6-karbonitril, hidroklorid sol;
ili tautomerni ili stereokemijski oblik, N-oksid, farmaceutski prihvatljivu sol ili solvat .
13. Farmaceutski pripravak koji obuhvaća spoj formule (I) sukladno bilo kojem od zahtjeva 1 to 12.
14. Farmaceutski pripravak koji obuhvaća spoj formule (I) sukladno bilo kojem od zahtjeva 1 do12, u kombinaciji s jednim ili više terapeutskih sredstava.
15. Spoj sukladno bilo kojem od zahtjeva 1 do 12:
(i) za uporabu u terapiji; ili
(ii) za uporabu u profilaksi ili liječenju bolesti ili stanja posredovanog IAP, poput XIAP i/ ili clAP; ili
(iii) za uporabu u profilaksi ili liječenju bolesti ili stanja koje prenaglašava IAP, poput XIAP i/ ili clAP; ili
(iv) za uporabu u profilaksi ili liječenju raka; ili
(v) za uporabu u profilaksi ili liječenju tumora epitelnog podrijetla (adenomi i karcinomi različitih vrste uključujući adenokarcinome, skvamozne karcinome, karcinome prijelaznih stanica i druge karcinome) kao što su karcinomi mokraćnog mjehura i mokraćnog sustava, dojke, gastrointestinalnog trakta (uključujući jednjak, želudac (želudac), tanko crijevo, debelo crijevo, rektum i anus), jetra (hepatocelularni karcinom), žučni mjehur i bilijarni sustav, egzokrina gušterača, bubreg, pluća (na primjer adenokarcinomi, karcinomi pluća malih stanica, karcinomi pluća nedrobnih stanica, bronhioalveolarni karcinomi i mezoteliomi), glave i vrata (na primjer karcinomi jezika, bukalne šupljine, grkljana, ždrijela, nazofarinksa, tonzila, žlijezda slinovnica, nosne šupljine i paranazalnih sinusa), jajnika, jajovoda, peritoneuma, rodnice, vulve, penisa, cerviksa, miometrija, endometrija, štitnjača (na primjer folikularni karcinom štitnjače), nadbubrežna žlijezda, prostata, koža i adneksi (na primjer melanom, karcinom bazalnih stanica, karcinom skvamoznih stanica, keratoakantom, displastični naevus); hematološki maligni (tj. leukemije, limfomi) i premaligni hematološki poremećaji i granični poremećaji malignosti, uključujući hematološke maligne bolesti i srodna stanja limfoidne loze (na primjer akutna limfocitna leukemija [ALL], kronična limfocitna leukemija [CLL], limfomi B-stanica poput difuzne velike B-stanični limfom [DLBCL], folikularni limfom, Burkittov limfom, limfom plaštnih ćelija, limfomi T-stanica i leukemije, limfomi stanica prirodnih ubojica [NK], Hodgkinovi limfomi, leukemija dlakavih stanica, monoklonska gamopatija neizvjesnog značaja, plazmocitom, multipli mijelom i post-transplantacijski limfoproliferativni poremećaji), te hematološki maligni i srodna stanja mijeloidne loze (na primjer akutni mijelogena leukemija [AML], kronična mijelogena leukemija [CML], kronična mijelomonocitna leukemija [CMML], hipereozinofilni sindrom, mijeloproliferativni poremećaji kao što je policitemija vera, esencijalna trombocitemija i primarna mijelofibroza, mijeloproliferativni sindrom, mijelodisplastični sindrom i promielocitna leukemija); tumori mezenhimskog porijekla, na primjer sarkomi mekog tkiva, kostiju ili hrskavice poput njih kao osteosarkomi, fibrosarkomi, hondrosarkomi, rabdomiosarkomi, leiomiosarkomi, liposarkomi, angiosarkomi, Kaposijev sarkom, Ewingov sarkom, sinovijalni sarkomi, epitelioidni sarkomi, gastrointestinalni stromalni tumori, benigni i maligni histiocitomi i dermatofibrosarkom protuberans; tumori središnji ili periferni živčani sustav (na primjer astrocitomi, gliomi i glioblastomi, meningiomi, ependimomi, tumori epifize i švanomi); endokrini tumori (na primjer tumori hipofize, nadbubrežne žlijezde tumori, otočni stanični tumori, paratireoidni tumori, karcinoidni tumori i medularni karcinom štitnjače); očni i adneksalni tumori (na primjer retinoblastom); zametnih stanica i trofoblastnih tumora (na primjer teratomi, seminomi, disgerminomi, hidatidiformni madeži i koriokarcinomi); i dječji i embrionalni tumori (na primjer meduloblastom, neuroblastom, Wilmsov tumor i primitivni neuroektodermal tumori); ili Xeroderma Pigmentosum;;
(vi) u kombinaciji s jednim ili više (npr. 1 ili 2) drugih terapeutskih agenasa (npr. antikancerski agensi); ili
(vii) u kombinaciji s jednim ili više (npr. 1 ili 2) drugih terapeutskih agenasa (npr. antikancerski agensi) za uporabu u terapiji, poput profilakse ili liječenja raka.
16. Spoj sukladno bilo kojem od zahtjeva 1 do 12 za uporabu u liječenju ili profilaksi raka, pri čemu je rak odabran od:
(i) hematoloških malignih bolesti i srodnih stanja limfoidne loze i hematoloških malignih bolesti i srodni uvjeti mijeloidne loze; i / ili
(ii) leukemije i limfomi; i / ili
(iii) akutna limfocitna leukemija [ALL], kronična limfocitna leukemija [CLL], limfomi B-stanica poput difuzne veliki B-stanični limfom [DLBCL], folikularni limfom, Burkittov limfom, limfom plaštnih ćelija, limfomi i leukemije T-stanica, limfomi prirodnih ubojica [NK] stanica, Hodgkinovi limfomi, leukemija dlakavih stanica, monoklonska gamopatija nesigurnog značaja, plazmacitom mijelom i limfoproliferativni poremećaji nakon transplantacije; i / ili
(iv) akutna mijelogena leukemija [AML], kronična mijelogena leukemija [CML], kronična mijelomonocitna leukemija [CMML], hipereozinofilni sindrom, mijeloproliferativni poremećaji, mijeloproliferativni sindrom, mijelodisplastični sindrom i promielocitna leukemija; i / ili
(v) refraktorni DLBCL.
17. Postupak za pripravu spoja formule (I) kako je definiran u bilo kojem od zahtjeva 1 do 12, naznačen time, da sadrži:
(I)
(a)
(i) reagirajući spoj formule (II):
[image]
pri čemu R1, R3a, R3b i R5 su sukladno bilo kojem od zahtjeva 1 do 11 i P1 predstavlja prikladnu zaštitnu skupinu poput tert-butiloksikarbonil (tBoc) skupina, sa spojem formule (III):
[image]
pri čemu R6, R7, R8, R9, p i E su sukladno bilo kojem od zahtjeva 1 do 11, praćen deprotekcijskom reakcijom P1 zaštitne skupine; ili
(ii) reagirajući spoj formule (III) sukladno gornjoj definiciji spoja formule (IV):
[image]
pri čemu R5 je sukladno bilo kojem od zahtjeva 1 do 11, i L1 i L2 neovisno predstavlja prikladnu preostalu skupinu poput halogena, zatim naknadna reakcija sa spojem formule (V):
[image]
pri čemu R1, R3a i R3b sukladno bilo kojem od zahtjeva 1 to 11 i P1 predstavlja hidrogen ili prikladnu zaštitnu skupinu poput tert-butiloksikarbonil (tBoc) skupina, praćen deprotekcijskom reakcijom koja može ukloniti P1 zaštitnu skupinu; i/ ili
(b) deprotekcija zaštićenog derivativa spoja formule (I); i/ ili
(c) interkonverzija spoja formule (I) ili zaštićeni derivativ do spoja formule (I) ili njegov zaštićeni derivativ; i
(d) opcionalna formulacija farmaceutski prihvatljive soli spoja formule (I); ili
(II) interkonverzija spoja formule (I) ili zaštićeni derivativ do spoja formule (I) ili njegov zaštićeni derivativ koji obuhvaća sljedeću reakciju:
[image]
pri čemu P1 predstavlja prikladnu zaštitnu skupinu poput tert-butiloksikarbonil (tBoc) skupine, i Het predstavlja 3-12 članu heterociklil skupinu koja može opcionalno biti supstituirana a jednom ili više Rb skupina i pri čemu Rb, R1, R5, R6, R7, R8, R9, E i p su sukladno bilo kojem od zahtjeva 1 to 11, praćen deprotekcijskom reakcijom koja može ukloniti P1 zaštitnu skupinu.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161477726P | 2011-04-21 | 2011-04-21 | |
GBGB1106817.8A GB201106817D0 (en) | 2011-04-21 | 2011-04-21 | New compound |
EP12717460.5A EP2699562B1 (en) | 2011-04-21 | 2012-04-20 | Bicyclic heterocycle compounds and their uses in therapy |
PCT/GB2012/050867 WO2012143726A1 (en) | 2011-04-21 | 2012-04-20 | Bicyclic heterocycle compounds and their uses in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210450T1 true HRP20210450T1 (hr) | 2021-04-30 |
Family
ID=44147398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210450TT HRP20210450T1 (hr) | 2011-04-21 | 2021-03-17 | Biciklički heterociklusni spojevi i njihova uporaba u terapiji |
Country Status (28)
Country | Link |
---|---|
US (6) | US9018214B2 (hr) |
EP (2) | EP3868747A1 (hr) |
JP (1) | JP6100238B2 (hr) |
KR (1) | KR101896134B1 (hr) |
CN (1) | CN103492376B (hr) |
AR (2) | AR086468A1 (hr) |
AU (1) | AU2012246081B2 (hr) |
BR (1) | BR112013027121B8 (hr) |
CA (1) | CA2831346C (hr) |
CY (1) | CY1123991T1 (hr) |
DK (1) | DK2699562T3 (hr) |
ES (1) | ES2855171T3 (hr) |
GB (1) | GB201106817D0 (hr) |
HR (1) | HRP20210450T1 (hr) |
HU (1) | HUE053688T2 (hr) |
IL (1) | IL228923A (hr) |
LT (1) | LT2699562T (hr) |
MX (1) | MX352564B (hr) |
MY (1) | MY168159A (hr) |
NZ (1) | NZ615572A (hr) |
PL (1) | PL2699562T3 (hr) |
PT (1) | PT2699562T (hr) |
RU (1) | RU2662827C2 (hr) |
SG (1) | SG193542A1 (hr) |
SI (1) | SI2699562T1 (hr) |
TW (1) | TWI558698B (hr) |
WO (1) | WO2012143726A1 (hr) |
ZA (1) | ZA201307797B (hr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201106814D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
GB201218862D0 (en) * | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
RU2696310C1 (ru) | 2013-12-20 | 2019-08-01 | Астекс Терапьютикс Лимитед | Бициклические гетероциклические соединения и их применение в терапии |
CA2943882A1 (en) | 2014-05-22 | 2015-11-26 | F. Hoffmann-La Roche Ag | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives |
PE20161476A1 (es) | 2014-06-26 | 2017-01-07 | Hoffmann La Roche | Derivados de indolin-2-ona o pirrolo-piridin-2-ona |
JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
EP3180312B1 (en) * | 2014-08-12 | 2019-10-16 | Loyola University Of Chicago | Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same |
ES2727379T3 (es) | 2014-12-03 | 2019-10-15 | Janssen Pharmaceutica Nv | Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5H)-ona y su uso como moduladores alostéricos negativos de receptores de mGlu2 |
ES2727158T3 (es) | 2014-12-03 | 2019-10-14 | Janssen Pharmaceutica Nv | Ligandos para PET de mGluR2 radiomarcados |
AU2016287581B2 (en) * | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
SI3389727T1 (sl) | 2015-12-18 | 2020-10-30 | Janssen Pharmaceutica Nv | Radioaktivno označeni ligandi PET MGLUR2/3 |
US11045562B2 (en) | 2015-12-18 | 2021-06-29 | Janssen Pharmaceutica Nv | Radiolabelled mGluR2/3 PET ligands |
JP2019514878A (ja) | 2016-04-20 | 2019-06-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Ripk2阻害剤を含むコンジュゲート |
CN109071525B (zh) * | 2016-05-09 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 二聚化合物 |
CN108690005B (zh) * | 2018-06-26 | 2021-08-24 | 兰州大学 | 含硝基天然产物chrysamides B合成方法及其非对映异构体-化合物 |
US11639354B2 (en) | 2018-07-31 | 2023-05-02 | Fimecs, Inc. | Heterocyclic compound |
CN111072549A (zh) * | 2018-10-19 | 2020-04-28 | 中国科学院兰州化学物理研究所苏州研究院 | 一种手性氧化吲哚螺环茚酮化合物及其合成方法 |
BR112021015149A2 (pt) * | 2019-02-02 | 2021-09-28 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Análogo de indolo heptamil oxima como inibidor de parp |
US20220402935A1 (en) | 2019-07-31 | 2022-12-22 | Fimecs, Inc. | Heterocyclic compound |
WO2021225955A1 (en) | 2020-05-04 | 2021-11-11 | Astex Pharmaceuticals, Inc. | Iap antagonist compounds and intermediates and methods for synthesizing the same |
IL298645A (en) * | 2020-06-04 | 2023-01-01 | Beigene Ltd | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazines as iap antagonists |
AR125043A1 (es) * | 2021-03-10 | 2023-05-31 | Acondicionamiento Tarrasense | Nuevos derivados de 2,3-dihidro-1h-pirrolo[3,2-b]piridina como ligandos sigma |
CN116731016A (zh) * | 2022-03-11 | 2023-09-12 | 苏州亚盛药业有限公司 | 作为iap拮抗剂的三环杂环化合物 |
WO2024071371A1 (ja) * | 2022-09-30 | 2024-04-04 | ユビエンス株式会社 | 複素環式化合物 |
CN118027138A (zh) * | 2022-11-07 | 2024-05-14 | 南京中澳转化医学研究院有限公司 | 吡啶酮类化合物及其制备方法、药物组合物和应用 |
CN116253756B (zh) * | 2023-05-11 | 2023-07-18 | 北京元延医药科技股份有限公司 | 克立硼罗的制备方法 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US4080330A (en) * | 1975-06-23 | 1978-03-21 | Delmar Chemicals Limited | Phenylindolines and process for their production |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
TW218875B (hr) | 1992-03-09 | 1994-01-11 | Takeda Pharm Industry Co Ltd | |
US5882864A (en) | 1995-07-31 | 1999-03-16 | Urocor Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
ATE243697T1 (de) | 1995-12-08 | 2003-07-15 | Pfizer | Substitutierte heterozyclische derivate als crf antagonisten |
EP0892780B1 (en) | 1996-02-22 | 2002-11-20 | Bristol-Myers Squibb Pharma Company | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS |
WO1997038665A2 (en) | 1996-04-03 | 1997-10-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2257950A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU7526798A (en) | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
BR9809092A (pt) | 1997-04-18 | 2002-01-22 | Smithkline Beecham Plc | Derivados de indol tendo atividade combinada de antagonista de receptor de 5ht1a, 5ht1b e 5ht1d |
US6557977B1 (en) | 1997-07-15 | 2003-05-06 | Silverbrook Research Pty Ltd | Shape memory alloy ink jet printing mechanism |
WO1999043670A1 (en) | 1998-02-26 | 1999-09-02 | Neurogen Corporation | Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists |
US6084098A (en) | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
RU2230740C2 (ru) | 1998-03-31 | 2004-06-20 | Акадиа Фармасьютикалз, Инк. | Производные азотсодержащих гетероциклических соединений и фармацевтическая композиция на их основе |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
KR20010085630A (ko) | 1998-08-26 | 2001-09-07 | 앤드류 앵뉴 | 세포 접착 억제를 조절하는 아자-비사이클 |
GB9905010D0 (en) | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
AU3555200A (en) | 1999-03-17 | 2000-10-04 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
GB9929552D0 (en) | 1999-12-14 | 2000-02-09 | Proteus Molecular Design | Compounds |
AU6762400A (en) | 1999-08-12 | 2001-03-13 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
JP2003508509A (ja) | 1999-09-04 | 2003-03-04 | アストラゼネカ アクチボラグ | ピルビン酸デヒドロゲナーゼの阻害剤としてのアミド |
GB0031088D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
EP1354882A1 (en) | 2000-12-27 | 2003-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
US6790845B2 (en) | 2001-04-09 | 2004-09-14 | Bristol-Myers Squibb Pharma Company | Fused heterocyclic inhibitors of factor Xa |
AU2002256418A1 (en) | 2001-04-27 | 2002-11-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
CA2483253A1 (en) | 2002-04-24 | 2003-11-06 | Takeda Pharmaceutical Company Limited | Use of compounds having ccr antagonism |
TW200402417A (en) * | 2002-06-21 | 2004-02-16 | Akzo Nobel Nv | 1-[(Indol-3-yl)carbonyl]piperazine derivatives |
KR20050114641A (ko) | 2003-03-07 | 2005-12-06 | 아스텔라스세이야쿠 가부시키가이샤 | 2,6-이치환된 스티릴을 갖는 질소 함유 헤테로환 유도체 |
GB0307891D0 (en) * | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
AU2004266233A1 (en) | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
TW200524887A (en) | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
ME02125B (me) | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
CN101035802A (zh) | 2004-07-02 | 2007-09-12 | 健泰科生物技术公司 | Iap抑制剂 |
WO2006010118A2 (en) | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
WO2006032987A1 (en) | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Indoline compounds and their use in the treatment of arteriosclerosis |
EA019420B1 (ru) | 2004-12-20 | 2014-03-31 | Дженентех, Инк. | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) |
BRPI0607988A2 (pt) | 2005-02-25 | 2009-10-27 | Tetralogic Pharmaceuticals | composto, composição farmacêutica, e método para induzir apoptose em uma célula |
CN101304989A (zh) | 2005-11-11 | 2008-11-12 | 弗·哈夫曼-拉罗切有限公司 | 作为凝血因子xa抑制剂的碳环稠合环胺 |
CN101374829A (zh) | 2005-12-19 | 2009-02-25 | 健泰科生物技术公司 | Iap的抑制剂 |
WO2007073405A1 (en) | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation |
FR2896504B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
GB0602335D0 (en) | 2006-02-07 | 2006-03-15 | Remynd Nv | Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases |
US20100016340A1 (en) | 2006-04-25 | 2010-01-21 | Astex Therapeutics Limited | Pharmaceutical compounds |
GB0608184D0 (en) * | 2006-04-25 | 2006-06-07 | Astex Therapeutics Ltd | Pharmaceutical compounds |
DK2019671T3 (en) * | 2006-05-05 | 2014-12-08 | Univ Michigan | Intermediates for the preparation of bivalent SMAC mimetics |
CL2007002166A1 (es) | 2006-07-24 | 2008-01-25 | Tetralogic Pharm Corp | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. |
RU2009117701A (ru) | 2006-10-12 | 2010-11-20 | Новартис АГ (CH) | Производные пирролидина в качестве ингибиторов iap |
KR20090086244A (ko) | 2006-12-07 | 2009-08-11 | 노파르티스 아게 | 증식성 질환의 치료에서의 6-옥소-1,6-디히드로피리미딘-2-일 |
US20080221094A1 (en) | 2007-03-07 | 2008-09-11 | Harald Bluhm | Metalloprotease inhibitors containing a squaramide moiety |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
NZ580468A (en) * | 2007-04-13 | 2012-02-24 | Univ Michigan | Diazo bicyclic smac mimetics and the uses thereof |
CN101827848B (zh) * | 2007-08-08 | 2012-11-07 | 葛兰素史密丝克莱恩有限责任公司 | 作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物 |
WO2009067233A1 (en) | 2007-11-20 | 2009-05-28 | Millennium Pharmaceuticals, Inc. | Beta carbolines and uses thereof |
CA2712604A1 (en) | 2008-01-24 | 2009-07-30 | Tetralogic Pharmaceutical Corporation | Iap inhibitors |
WO2009147476A1 (en) | 2008-06-02 | 2009-12-10 | Matrix Laboratories Ltd. | Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation |
WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
SG174146A1 (en) | 2009-02-27 | 2011-10-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
AU2010254056A1 (en) * | 2009-05-28 | 2011-12-15 | Tetralogic Pharmaceuticals Corp. | IAP inhibitors |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
GB201106814D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
EP2763531A4 (en) | 2011-10-03 | 2015-11-18 | Univ Columbia | NOVEL MOLECULES THAT INHIBIT HISTONE-DEACETYLASE 6 WITHIN HISTONE-DEACETYLASE 1 |
NZ626973A (en) | 2012-01-06 | 2016-09-30 | Novartis Ag | Heterocyclic compounds and methods for their use |
GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
RU2696310C1 (ru) | 2013-12-20 | 2019-08-01 | Астекс Терапьютикс Лимитед | Бициклические гетероциклические соединения и их применение в терапии |
CA2935944A1 (en) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
WO2021225955A1 (en) | 2020-05-04 | 2021-11-11 | Astex Pharmaceuticals, Inc. | Iap antagonist compounds and intermediates and methods for synthesizing the same |
JP2023524744A (ja) | 2020-05-04 | 2023-06-13 | 大塚製薬株式会社 | 無水乳酸を合成する方法 |
-
2011
- 2011-04-21 GB GBGB1106817.8A patent/GB201106817D0/en not_active Ceased
-
2012
- 2012-04-20 AR ARP120101376A patent/AR086468A1/es active IP Right Grant
- 2012-04-20 SG SG2013070537A patent/SG193542A1/en unknown
- 2012-04-20 ES ES12717460T patent/ES2855171T3/es active Active
- 2012-04-20 PL PL12717460T patent/PL2699562T3/pl unknown
- 2012-04-20 TW TW101114165A patent/TWI558698B/zh active
- 2012-04-20 EP EP20214100.8A patent/EP3868747A1/en active Pending
- 2012-04-20 CN CN201280019180.7A patent/CN103492376B/zh active Active
- 2012-04-20 LT LTEP12717460.5T patent/LT2699562T/lt unknown
- 2012-04-20 CA CA2831346A patent/CA2831346C/en active Active
- 2012-04-20 NZ NZ615572A patent/NZ615572A/en unknown
- 2012-04-20 MY MYPI2013003401A patent/MY168159A/en unknown
- 2012-04-20 US US14/112,597 patent/US9018214B2/en active Active
- 2012-04-20 KR KR1020137030536A patent/KR101896134B1/ko active IP Right Grant
- 2012-04-20 EP EP12717460.5A patent/EP2699562B1/en active Active
- 2012-04-20 HU HUE12717460A patent/HUE053688T2/hu unknown
- 2012-04-20 AU AU2012246081A patent/AU2012246081B2/en active Active
- 2012-04-20 WO PCT/GB2012/050867 patent/WO2012143726A1/en active Application Filing
- 2012-04-20 SI SI201231896T patent/SI2699562T1/sl unknown
- 2012-04-20 DK DK12717460.5T patent/DK2699562T3/da active
- 2012-04-20 BR BR112013027121A patent/BR112013027121B8/pt active IP Right Grant
- 2012-04-20 MX MX2013012243A patent/MX352564B/es active IP Right Grant
- 2012-04-20 JP JP2014505721A patent/JP6100238B2/ja active Active
- 2012-04-20 RU RU2013151803A patent/RU2662827C2/ru active
- 2012-04-20 PT PT127174605T patent/PT2699562T/pt unknown
-
2013
- 2013-10-17 IL IL228923A patent/IL228923A/en active IP Right Grant
- 2013-10-18 ZA ZA2013/07797A patent/ZA201307797B/en unknown
-
2015
- 2015-03-20 US US14/663,534 patent/US9676768B2/en active Active
-
2017
- 2017-05-03 US US15/585,908 patent/US20170334907A1/en not_active Abandoned
-
2019
- 2019-05-10 US US16/409,364 patent/US20190375748A1/en not_active Abandoned
- 2019-11-05 AR ARP190103237A patent/AR116993A2/es unknown
-
2020
- 2020-09-28 US US17/034,926 patent/US11866428B2/en active Active
-
2021
- 2021-03-17 HR HRP20210450TT patent/HRP20210450T1/hr unknown
- 2021-03-22 CY CY20211100240T patent/CY1123991T1/el unknown
-
2023
- 2023-11-01 US US18/499,940 patent/US20240199607A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210450T1 (hr) | Biciklički heterociklusni spojevi i njihova uporaba u terapiji | |
EP3414247B1 (en) | Spiroindolinones as ddr1 inhibitors | |
JP7284830B2 (ja) | タンパク質チロシンホスファターゼ阻害剤 | |
AU2011273931B2 (en) | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | |
CN107652289B (zh) | 作为fgfr抑制剂的取代的三环化合物 | |
TWI476198B (zh) | 新穎之吲嗪化合物、其製備方法及含彼之醫藥組合物 | |
JP6914933B2 (ja) | ヤヌスキナーゼ、並びにその組成物及びその使用 | |
ES2834462T3 (es) | Compuestos heterocíclicos bicíclicos y sus usos en terapia | |
JP5876596B2 (ja) | カゼインキナーゼ阻害剤としての新規縮合ピリジン化合物 | |
JP6900491B2 (ja) | ピラゾロピリミジン化合物及びその使用方法 | |
WO2020210828A1 (en) | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions | |
EP3416967A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
CA3160988A1 (en) | Allosteric egfr inhibitors and methods of use thereof | |
JP5219150B2 (ja) | キナーゼ阻害薬として活性な置換ピラゾロ[4,3−c]ピリジン誘導体 | |
JP2010519226A (ja) | 5−ht6受容体親和性を有する6’位置換インドール及びインダゾール誘導体 | |
WO2023156386A2 (en) | Pharmaceutical compound | |
JP2023529701A (ja) | アロステリックegfr阻害剤及びその使用方法 | |
WO2018166993A2 (en) | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | |
JP2022536805A (ja) | Jakキナーゼのテトラゾール置換ピラゾロピリミジン阻害剤及びその使用 |